var title_f10_34_10784="SVC syndrome SCLC";
var content_f10_34_10784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior vena cava syndrome from small cell lung carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A peripheral nodule is visible in the posterior segment of the right upper lobe with adjacent large right paratracheal lymph nodes (white arrows) completely occluding the superior vena cava. Collateral vessels drain the contrast enhanced venous blood towards the inferior vena cava. The internal mammary veins, the left superior intercostal vein, the lateral thoracic vein and the paravertebral veins are clearly visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10784=[""].join("\n");
var outline_f10_34_10784=null;
var title_f10_34_10785="Tinea versicolor chest PI";
var content_f10_34_10785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor on the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor can appear as dark patches on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Paul S Matz, MD. Reproduced from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10785=[""].join("\n");
var outline_f10_34_10785=null;
var title_f10_34_10786="Mucosal telangiectasias in HHT";
var content_f10_34_10786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucosal telangiectasias in hereditary hemorrhagic telangectasia (Osler Weber Rendu syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial telangectasias are seen on the lips of a man with hereditary hemorrhagic telangectasia syndrome who had a solitary pulmonary arteriovenous malformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Gossage JR, Kanj G, Am J Respir Crit Care Med 1998; 158:643",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10786=[""].join("\n");
var outline_f10_34_10786=null;
var title_f10_34_10787="EB simplex variants";
var content_f10_34_10787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77709%7EDERM%2F67202%7EDERM%2F55262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77709%7EDERM%2F67202%7EDERM%2F55262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genotypic and phenotypic variants of epidermolysis bullosa simplex (epidermolytic)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site of cleavage within the epidermis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subtypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Inheritance",
"        </p>",
"        <p>",
"         Mutated gene",
"        </p>",
"        <p>",
"         Targeted gene product",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <p>",
"         <strong>",
"          Suprabasal",
"         </strong>",
"        </p>",
"        <p>",
"         (cytolysis of suprabasal keratinocytes; intact blisters usually not clinically evident; keratinocytes form numerous interdigitating cellular protrusions; only few desmosomal remnants present)",
"        </p>",
"       </td>",
"       <td>",
"        EB, lethal acantholytic",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          DSP",
"         </em>",
"        </p>",
"        <p>",
"         Desmoplakin",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Two cases of LAEB have been described",
"          <sup>",
"           [1,2]",
"          </sup>",
"         </li>",
"         <li>",
"          Generalized skin fragility with rapidly progressive epidermolysis and large sheets of detached skin with superficial erosions at birth; skin detachment on hands and feet in a glove and stocking pattern; complete disruption of the epidermal barrier without intact blisters or vesicles; no excessive granulation tissue",
"         </li>",
"         <li>",
"          Universal alopecia (complete absence of scalp hair, eyebrows, eyelashes despite discrete follicular openings on scalp) and nail loss neonatal teeth",
"         </li>",
"         <li>",
"          Involvement of oropharynx, gastrointestinal, genitourinary, and respiratory tract with extensive suprabasal acantholytic separation",
"         </li>",
"         <li>",
"          Demise in neonatal period",
"          <sup>",
"           [1]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         EB, lethal congenital",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          JUP",
"         </em>",
"        </p>",
"        <p>",
"         Plakoglobin",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          One patient described",
"          <sup>",
"           [3]",
"          </sup>",
"         </li>",
"         <li>",
"          Loss of immunohistochemical reactivity to plakoglobin, desmoplakin, desmoglein-3",
"         </li>",
"         <li>",
"          Generalized erythema and epidermolysis with massive transcutaneous fluid loss",
"         </li>",
"         <li>",
"          Total alopecia, onycholysis",
"         </li>",
"         <li>",
"          No involvement of mucous membranes",
"         </li>",
"         <li>",
"          Proneness to infection (Aspergillus fumigates sepsis), purpura fulminans",
"         </li>",
"         <li>",
"          Massive coprostasis",
"         </li>",
"         <li>",
"          Demise in neonatal period",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectodermal dysplasia-skin fragility syndrome/plakophilin deficiency",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          PKP1",
"         </em>",
"        </p>",
"        <p>",
"         Plakophilin-1",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized skin fragility with trauma-induced and spontaneous superficial erosions from birth; palmoplantar keratoderma with painful, often disabling fissures (walking, bearing weight); nail dystrophy; alopecia",
"         </li>",
"         <li>",
"          Chronic cheilitis, perioral scale, perioral and lingual fissures",
"         </li>",
"         <li>",
"          Blepharitis, astigmatism",
"         </li>",
"         <li>",
"          Persistent abnormal hair (hypotrichosis, loss of eyelashes, complete alopecia; woolly hair)",
"         </li>",
"         <li>",
"          Esophageal strictures, constipation",
"         </li>",
"         <li>",
"          Growth retardation (usually below the third centile for height and weight)",
"         </li>",
"         <li>",
"          Variable clinical features include scattered scale-crust on the trunk and limbs, follicular hyperkeratosis, inflammatory scaly plaques in flexures, perianal erythema and erosions, pruritus; reduced sweating; dental caries; recurrent systemic infections; chronic diarrhea",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS superficialis",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         ?",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blistering between stratum corneum and granulosom",
"         </li>",
"         <li>",
"          Superficial erosions with scarring and milia formation from birth or early infancy",
"          <sup>",
"           [4]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        <p>",
"         <strong>",
"          Basal",
"         </strong>",
"        </p>",
"        <p>",
"         (cytolysis of basal keratinocytes)",
"        </p>",
"       </td>",
"       <td>",
"        EBS, localized, former Weber-Cockayne",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         <em>",
"          KRT5",
"         </em>",
"         ,",
"         <em>",
"          KRT14",
"         </em>",
"         ,",
"         <em>",
"          ITGB4",
"         </em>",
"        </p>",
"        <p>",
"         Keratin 5, keratin 14, integrin&alpha;4",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Most common EBS subtype",
"         </li>",
"         <li>",
"          Mainly limited, regional involvement of palms and soles",
"         </li>",
"         <li>",
"          Clinical onset usually during infancy or, rarely, early adulthood",
"         </li>",
"         <li>",
"          Extracutaneous manifestations (other than clinically insignificant blisters within oral cavity during early childhood) rare",
"          <sup>",
"           [5]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS, Dowling-Meara",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         <em>",
"          KRT5",
"         </em>",
"         ,",
"         <em>",
"          KRT14",
"         </em>",
"        </p>",
"        <p>",
"         Keratin 5, keratin 14",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized, peculiar herpetiform distribution (arcuate grouping) of blisters from birth (typically and best seen when patients have relatively milder disease activity",
"          <sup>",
"           [6]",
"          </sup>",
"          )",
"         </li>",
"         <li>",
"          Atrophic scarring, milia formation, confluent palmoplantar hyperkeratosis, nail manifestations",
"         </li>",
"         <li>",
"          Often mucosal involvement",
"         </li>",
"         <li>",
"          Association with growth retardation, anemia (fatigue, breathlessness, reduced exercise tolerance, poor wound healing, anorexia), constipation, laryngeal stenosis, premature death",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS, other generalized, including former Koebner",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant or recessive",
"        </p>",
"        <p>",
"         <em>",
"          KRT5",
"         </em>",
"         ,",
"         <em>",
"          KRT14",
"         </em>",
"         ,",
"         <em>",
"          COL17A1",
"         </em>",
"        </p>",
"        <p>",
"         Keratin 5, keratin 14, type XVII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Widespread but less severe form that usually presents at birth",
"         </li>",
"         <li>",
"          Rarely eye involvement",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS with mottled pigmentation",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         <em>",
"          KRT5",
"         </em>",
"        </p>",
"        <p>",
"         Keratin 5",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Skin blistering with reticulate brown skin pigmentation, keratoderma, nail dystrophy",
"         </li>",
"         <li>",
"          Pigmentary lesions usually present in early childhood, but may become less distinctive or even imperceptible by adult life",
"          <sup>",
"           [6]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS with muscular dystrophy",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive (autosomal dominant)",
"        </p>",
"        <p>",
"         <em>",
"          PLEC1",
"         </em>",
"        </p>",
"        <p>",
"         Plectin",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth",
"         </li>",
"         <li>",
"          Atrophic scarring, milia formation, nail dystrophy and loss",
"         </li>",
"         <li>",
"          Granulation tissue formation and stenosis within respiratory tract",
"         </li>",
"         <li>",
"          Muscular dystrophy may either be present on or shortly after birth in a child with severe generalized skin involvement (usually appearing as \"floppy\" babies who are unable to easily lift their arms and legs), or, in others, may arise insidiously in later childhood or adulthood; this variant harbours a higher mortality rate from muscle involvement",
"          <sup>",
"           [5]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS with pyloric atresia",
"       </td>",
"       <td>",
"        <p>",
"         ?",
"        </p>",
"        <p>",
"         <em>",
"          PLEC1",
"         </em>",
"         ,",
"         <em>",
"          ITGA6",
"         </em>",
"         ,",
"         <em>",
"          ITGB4",
"         </em>",
"        </p>",
"        <p>",
"         Plectin, integrin&alpha;6, integrin &beta;4",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Gestational hydramnion",
"         </li>",
"         <li>",
"          Generalized blistering of variable severity from birth, atrophic scarring",
"          <sup>",
"           [7-9]",
"          </sup>",
"         </li>",
"         <li>",
"          Association with aplasia cutis congenital",
"          <sup>",
"           [10]",
"          </sup>",
"         </li>",
"         <li>",
"          Mucosal involvement (protein losing enteropathy, diarrhea)",
"         </li>",
"         <li>",
"          Anemia, growth retardation, contractures, cryptorchidism, high mortality",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS, autosomal recessive",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          KRT14",
"         </em>",
"         ,",
"         <em>",
"          DST",
"         </em>",
"         <sup>",
"          [11]",
"         </sup>",
"        </p>",
"        <p>",
"         Keratin 14, distonin (BPAG1)",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth (frequently anogenital), ichthyosiform plaques; rarely milia formation or atrophic scarring",
"         </li>",
"         <li>",
"          Involvement of oral cavity (caries) and genitourinary tract",
"         </li>",
"         <li>",
"          Growth retardation, constipation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBS, Ogna type",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         <em>",
"          PLEC1",
"         </em>",
"        </p>",
"        <p>",
"         Plectin",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Hemorrhagic blisters at predominantly acral sites from birth",
"         </li>",
"         <li>",
"          Onychogryphosis (markedly curved and deformed nails resembling ram's horns)",
"          <sup>",
"           [6]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Jonkman MF, Pasmooij AM, Pasmans SG, et al. Loss of desmoplakin tail causes lethal acantholytic Epidermolysis bullosa. Am J HumGenet 2005; 77:653.",
"       </li>",
"       <li>",
"        Bolling MC, Veenstra MJ, Jonkman MF, et al. Lethal acantholytic epidermolysis bullosa due to a novel homozygous deletion in DSP: Expanding the phenotype and implications for desmoplakin function in skin and heart. Br J Dermatol 2010; 162:1388.",
"       </li>",
"       <li>",
"        Pigors M, Kiritsi D, Kr&uuml;mpelmann S, et al. Lack of plakoglobin leads to lethal congenital epidermolysis bullosa: a novel clinico-genetic entity. Hum Mol Genet 2011; 20:1811.",
"       </li>",
"       <li>",
"        Fine JD, Johnson L, Wright T. Epidermolysis bullosa simplex superficialis. A new variant of epidermolysis bullosa characterized by subcorneal skin cleavage mimicking peeling skin syndrome. Arch Dermatol 1989; 125:633.",
"       </li>",
"       <li>",
"        Lanschuetzer CM, Fine JD. Classification and molecular basis of hereditary epidermolysis. In: Life with Epidermolysis Bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy, Fine JD, Hintner H (Eds), Springer, Wien-New York 2008. p.6.",
"       </li>",
"       <li>",
"        Fine JD. General cutaneous manifestations. In: Life with Epidermolysis Bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy, Fine JD, Hintner H (Eds), Springer, Wien, New York 2008. p.99.&nbsp;&nbsp;",
"       </li>",
"       <li>",
"        Mellerio JE, Pulkkinen L, McMillan JR, et al. Pyloric atresia-junctional epidermolysis bullosa syndrome: Mutations in the integrin beta4 gene (ITGB4) in two unrelated patients with mild disease. Br J Dermatol 1998; 139:862.",
"       </li>",
"       <li>",
"        Nakano A, Pulkkinen L, Murrell D, et al. Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. Pediatr Res 2001; 49:618.",
"       </li>",
"       <li>",
"        Pulkkinen L, Kim DU, Uitto J. Epidermolysis bullosa with pyloric atresia: Novel mutations in the beta4 integrin gene (ITGB4). Am J Pathol 1998; 152:157.",
"       </li>",
"       <li>",
"        Maman E, Maor E, Kachko L, Carmi R. Epidermolysis bullosa, pyloric atresia, aplasia cutis congenita: Histopathological delineation of an autosomal recessive disease. Am J Med Genet 1998; 78:127.",
"       </li>",
"       <li>",
"        Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010; 130:1551.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Inheritance",
"        </p>",
"        <p>",
"         Mutated gene",
"        </p>",
"        <p>",
"         Targeted gene product",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JEB, Herlitz",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          LAMA3",
"         </em>",
"         ,",
"         <em>",
"          LAMB3",
"         </em>",
"         ,",
"         <em>",
"          LAMC2",
"         </em>",
"        </p>",
"        <p>",
"         Laminin &alpha;3 chain of laminin-332",
"         <br/>",
"         Laminin &beta;3 chain of laminin-332",
"         <br/>",
"         Laminin &chi;2 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Profound mechanical fragility at birth with extensive generalized, recurrent, often persistent blistering, erosions, and&nbsp;crusting covering not only particularly exposed skin areas (like palms and soles) but most or almost all of the body surface",
"         </li>",
"         <li>",
"          Scarring alopecia, milia, onychodystrophy, and nail loss",
"         </li>",
"         <li>",
"          Pseudosyndactyly",
"         </li>",
"         <li>",
"          Exuberant (periorificial) granulation tissue",
"         </li>",
"         <li>",
"          Involvement of oral cavity (microstomia, ankyloglossia), teeth (enamel hypoplasia, excessive caries), gastrointestinal (protein losing enteropathy, diarrhea), respiratory, genitourinary tract, conjunctivae",
"         </li>",
"         <li>",
"          Anemia, growth retardation, delayed puberty, high lethality",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, non Herlitz, generalized",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL17A1",
"         </em>",
"         ,",
"         <em>",
"          LAMA3",
"         </em>",
"         ,",
"         <em>",
"          LAMB3",
"         </em>",
"         ,",
"         <em>",
"          LAMC2",
"         </em>",
"        </p>",
"        <p>",
"         Type XVII collagen",
"         <br/>",
"         Laminin &alpha;3 chain of laminin-332",
"         <br/>",
"         Laminin &beta;3 chain of laminin-332",
"         <br/>",
"         Laminin &chi;2 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth, atrophic scarring, milia; \"male-pattern\" alopecia; nail dystrophy and loss",
"         </li>",
"         <li>",
"          Involvement of oral cavity and teeth (excessive caries, teeth loss, enamel hypoplasia), gastrointestinal, respiratory and genitourinary tract, conjunctivae",
"         </li>",
"         <li>",
"          Anemia, growth retardation, protein losing enteropathy,&nbsp;diarrhea",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, non Herlitz, localized",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL17A1",
"         </em>",
"        </p>",
"        <p>",
"         Type XVII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Localized disease of lesser extent and lesser severity, onset at birth; milia, nail dystrophy and loss",
"         </li>",
"         <li>",
"          Involvement of oral cavity and teeth (excessive caries, enamel hypoplasia)",
"         </li>",
"         <li>",
"          Extensive atrophic scarring, hair loss, anemia, impairments of growth and development, ocular abnormalities or alterations affecting gastrointestinal, genitourinary, respiratory tract mostly absent",
"          <sup>",
"           [1]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB with pyloric atresia",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          ITGA6",
"         </em>",
"         ,",
"         <em>",
"          ITGB4",
"         </em>",
"        </p>",
"        <p>",
"         Integrin &alpha;6, Integrin &beta;4",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Gestational hydramnion",
"         </li>",
"         <li>",
"          Generalized and profound blistering from birth, occasionally age-associated amelioration; atrophic scarring; nail dystrophy and loss",
"         </li>",
"         <li>",
"          Association with aplasia cutis congenita",
"         </li>",
"         <li>",
"          Enamel hypoplasia",
"         </li>",
"         <li>",
"          Pyloric atresia",
"         </li>",
"         <li>",
"          Congenital genitourinary malformations",
"         </li>",
"         <li>",
"          Sporadically rudimentary ear anlage",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, inversa",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          LAMA3",
"         </em>",
"         ,",
"         <em>",
"          LAMB3",
"         </em>",
"         ,",
"         <em>",
"          LAMC2",
"         </em>",
"        </p>",
"        <p>",
"         Laminin &alpha;3 chain of laminin-332",
"         <br/>",
"         Laminin &beta;3 chain of laminin-332",
"         <br/>",
"         Laminin &chi;2 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blistering predominantly located in intertringinous areas/sites, typically displaying an overall extent that exceeds that observed in patients with JEB-nH, localized",
"          <sup>",
"           [1]",
"          </sup>",
"         </li>",
"         <li>",
"          Atrophic scarring, milia, hypo-/hyperpigmentation, dystrophic (or absent) nails",
"         </li>",
"         <li>",
"          Moderate oral mucosal lesions; dental enamel hypoplasia, caries and gastrointestinal abnormalities to a lesser extent as compared to other JEB-nH variants",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, late onset (former progressiva)",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         ?",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Mild form of JEB developing in young adulthood or later",
"         </li>",
"         <li>",
"          Dystrophic (or absent) nails, dental enamel hypoplasia and caries to a lesser severity than JEB-nH",
"         </li>",
"         <li>",
"          Hyperhidrosis",
"         </li>",
"         <li>",
"          Absence of dermatoglyphs on fingers, palms, toes and soles",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Laryngo-onycho-cutaneous syndrome",
"        <sup>",
"         [2-5]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          LAMA3A",
"         </em>",
"        </p>",
"        <p>",
"         Laminin &alpha;3 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          High incidence in Punjab",
"         </li>",
"         <li>",
"          Minimal skin blistering, erosions",
"         </li>",
"         <li>",
"          Extensive aberrant production of granulation tissue with delayed healing, atrophic scarring",
"         </li>",
"         <li>",
"          Involvement of larynx (altered cry) at birth, skin (face, nuchal) and conjunctiva (granulomatous papules, symblepharon) in infancy",
"         </li>",
"         <li>",
"          Nail dystrophy and loss",
"         </li>",
"         <li>",
"          Enamel hypoplasia, caries",
"         </li>",
"         <li>",
"          High childhood mortality due to laryngeal, gastrointestinal, and urethral strictures",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.",
"       </li>",
"       <li>",
"        Shabbir G, Hassan M, Kazmi A. Laryngo-onycho-cutaneous syndrome: A study of 22 cases. Biomedica 1986; 2:15.",
"       </li>",
"       <li>",
"        Ainsworth JR, Spencer AF, Dudgeon J, et al. Laryngeal and ocular granulation tissue formation in two Punjabi children: LOGIC syndrome. Eye (Lond) 1991; 5:717.",
"       </li>",
"       <li>",
"        Ainsworth JR, Shabbir G, Spencer AF, Cockburn F. Multisystem disorder of Punjabi children exhibiting spontaneous dermal and submucosal granulation tissue formation: LOGIC syndrome. Clin Dysmorphol 1992; 1:3.",
"       </li>",
"       <li>",
"        Phillips RJ, Atherton DJ, Gibbs ML, et al. Laryngo-onycho-cutaneous syndrome: An inherited epithelial defect. Arch Dis Child 1994; 70:319.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genotypic and phenotypic variants of dystrophic epidermolysis bullosa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Inheritance",
"        </p>",
"        <p>",
"         Mutated gene",
"        </p>",
"        <p>",
"         Targeted gene product",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Dominant DEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant DEB, generalized",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth, atrophic scarring, dystrophic (or absent) nails; alopecia",
"         </li>",
"         <li>",
"          \"Albopapuloid\" lesions (small grouped hypopigmented papules usually on the lower back)",
"         </li>",
"         <li>",
"          Pseudosyndaktyly",
"         </li>",
"         <li>",
"          Involvement of oral cavity, gastrointestinal and, rarely, genitourinary tract",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant DEB, acral",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant, autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Predilection of blistering for hands and feet from early infancy, milia, atrophic scarring, dystrophic (or absent) nails",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant DEB, pretibial",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant, autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Pretibial blistering from birth or early infancy, involvement of hands and feet, milia, atrophic scarring; dystrophic nails",
"         </li>",
"         <li>",
"          Lichen planus-like skin lesions",
"         </li>",
"         <li>",
"          Excessive caries, constipation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant DEB, pruriginosa",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant, autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized or localized erosions, blisters, milia and atrophic scars from infancy; dystrophic nails",
"         </li>",
"         <li>",
"          Pronounced pruritus",
"         </li>",
"         <li>",
"          Constipation",
"         </li>",
"         <li>",
"          Possibly higher risk for development of squamous cell carcinoma in middle age",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant DEB, nails only",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Nail dystrophy or loss at birth or infancy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant DEB, bullous dermolysis of the newborn",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant, autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth or early infancy, milia, atrophic scarring; dystrophic nails; excessive caries",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Recessive DEB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, severe generalized (former recessive DEB-Hallopeau-Siemens)",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth, atrophic scarring, milia; sparse hair with scarring alopecia; dystrophic or absent nails; multiple angiomas",
"         </li>",
"         <li>",
"          Acral pseudosyndaktyly and contractures",
"         </li>",
"         <li>",
"          Involvement of oral cavity (excessive caries), gastrointestinal (protein losing enteropathy) and genitourinary tract (glomerulonephritis, IgA-nephropathy, chronic renal failure), conjunctivae",
"         </li>",
"         <li>",
"          Tremendous risk for development of squamous cell carcinomas",
"         </li>",
"         <li>",
"          Cardiomyopathy, osteoporosis, anemia, impaired growth, delayed puberty",
"         </li>",
"         <li>",
"          High lethality",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, other",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering at birth, continue to develop throughout life; atrophic scarring, milia; nail dystrophy; scarring alopecia",
"         </li>",
"         <li>",
"          Pseudosyndaktyly",
"         </li>",
"         <li>",
"          Increased risk for development of squamous cell carcinomas",
"         </li>",
"         <li>",
"          Involvement of oral cavity, gastrointestinal and genitourinary tract, conjunctivae",
"         </li>",
"         <li>",
"          Anemia, growth retardation",
"         </li>",
"         <li>",
"          Increased lethality",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, inversa",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blistering predominantly located in intertringinous lumbosacral, acral and axial areas; milia, atrophic scarring; nail dystrophy;",
"         </li>",
"         <li>",
"          Involvement of oral cavity (caries), gastrointestinal and genitourinary tract",
"         </li>",
"         <li>",
"          Stenosis of meatus acusticus externus",
"         </li>",
"         <li>",
"          Anemia, growth retardation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, pretibial",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant, autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Pretibial blistering at birth or early infancy, involvement of hands and feet; milia; atrophic scarring; nail dystrophy",
"         </li>",
"         <li>",
"          Lichen planus-like skin lesions",
"         </li>",
"         <li>",
"          Excessive caries, constipation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, acral",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant, autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blistering on hands and feet from early infancy, milia, atrophic scarring; nail dystrophy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, pruriginosa",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized or localized erosions, blisters, milia and atrophic scars from infancy; dystrophic nails",
"         </li>",
"         <li>",
"          Excessive pruritus",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, centropedalis",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Pretibial and acral blistering at birth or from early infancy, milia, atrophic scarring; nail dystrophy",
"         </li>",
"         <li>",
"          Involvement of oral mucosa",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recessive DEB, bullous dermolysis of the newborn",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL7A1",
"         </em>",
"        </p>",
"        <p>",
"         Type VII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth or early infancy, milia, atrophic scarring; dystrophic nails",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10787=[""].join("\n");
var outline_f10_34_10787=null;
var title_f10_34_10788="Left hemicolectomy for a benign process";
var content_f10_34_10788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left hemicolectomy for a benign process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a resection of the left colon for a benign process, such as colitis. The mesentery is&nbsp; not resected at its root, adn care must be taken to anastomose the bowel in areas of adequate blood supply. I WILL WORK ON THIS LATER!",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10788=[""].join("\n");
var outline_f10_34_10788=null;
var title_f10_34_10789="Adefovir: Pediatric drug information";
var content_f10_34_10789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Adefovir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"    see \"Adefovir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30133?source=see_link\">",
"    see \"Adefovir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hepsera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hepsera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F996369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F996398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"      see \"Adefovir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 years and Adolescents:",
"     <b>",
"      Hepatitis B infection, chronic:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Optimal duration of treatment not established, continuation of therapy for at least 6 months after sero-conversion has been suggested (Jonas, 2010). Prolonged therapy (4 years) has been reported to be safe and well-tolerated in pediatric patients (2-18 years). Patients not achieving a &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Jonas, 2012; Lok, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2 to &lt;7 years: Limited data available; efficacy results variable: Oral: 0.3 mg/kg/dose once daily; maximum dose: 10 mg (Jonas, 2008; Jonas, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;7 to &lt;12 years:  Limited data available; efficacy results variable: Oral: 0.25 mg/kg/dose once daily; maximum dose: 10 mg (Jonas, 2008; Jonas, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents: Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Hepatitis B infection, chronic:",
"     </b>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment duration (AASLD practice guidelines):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving a &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; no data available; consider dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s labeling: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 10 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 10 mg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: There are no dosage adjustments provided in manufacturer's labeling; no data available in nonhemodialysis patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis: 10 mg every 7 days (following dialysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     The following guidelines have been used by some clinicians (Aronoff, 2007): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: 10 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;19 mL/minute: 10 mg every 72 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dipivoxil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepsera&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F996404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F996387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F996370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis B with evidence of active viral replication and either persistent elevations of ALT or AST or histologically active disease (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F130645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, renal failure, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Fanconi syndrome, hepatitis, myopathy, nephrotoxicity, osteomalacia, pancreatitis, proximal renal tubulopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F996374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to adefovir or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14730090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Efficacy in pediatric patients &lt;12 years has not been reported; in clinical trials of children 2-12 years, positive responses to adefovir therapy were observed (13% to 17% of subjects evaluated); however, findings did not reach statistical significance (Jonas, 2008). Use with caution in patients with decompensated liver function and prolonged use (&gt;1 year) due to high rate of resistance accompanied by rebound increase viral load which may further decrease liver function (and possibly fatal outcome). Not recommended as first-line therapy of chronic HBV due to weak antiviral activity and high rate of resistance; may be more appropriate as second-line agent in treatment-na&iuml;ve patients. Combination therapy with lamivudine in nucleoside-na&iuml;ve patients has not been shown to provide synergistic antiviral effects. In patients with lamivudine-resistant HBV, switching to adefovir monotherapy was associated with a higher risk of adefovir resistance compared to adding adefovir to lamivudine therapy (Lok, 2009). Do not use concurrently with tenofovir (Viread&reg;) or any product containing tenofovir (eg, Truvada&reg;, Atripla&reg;, Complera&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F996375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe, acute exacerbation of hepatitis B may occur upon discontinuation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; exacerbations (ALT elevation &ge;10 times ULN) may occur in up to 25% of patients and usually within 12 weeks; may be self-limited or resolve upon resuming treatment; risk may be increased with advanced liver disease or cirrhosis. Monitor liver function several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic administration may result in treatment-limiting nephrotoxicity in patients at risk for or with underlying renal dysfunction",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; nephrotoxicity is characterized by gradual increase in serum creatinine and decrease in serum phosphorus; use with caution in patients with renal dysfunction or in patients at risk for development of nephrotoxicity including those on concurrent nephrotoxic agents (eg, cyclosporine, tacrolimus, aminoglycosides, vancomycin, or NSAIDs); dosage adjustment may be required in patients with pre-existing renal dysfunction or in those who develop renal dysfunction during therapy. Calculate creatinine clearance before initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause the development of HIV resistance in patients with unrecognized or untreated HIV infection",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; determine HIV status prior to initiating treatment with adefovir.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal cases of lactic acidosis and severe hepatomegaly with steatosis have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with risk factors for liver disease; risk may be increased with female gender, obesity, pregnancy, and prolonged treatment; suspend  if clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may or may not accompany hepatomegaly and steatosis).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Adefovir may diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only when clearly needed. Pregnant women exposed to adefovir should be registered with the pregnancy registry (800-258-4263).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F996406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV status (prior to initiation of therapy); serum creatinine (prior to initiation and during therapy); LFTs for several months following discontinuation of adefovir; HBV DNA (every 3-6 months during therapy); HBeAg and anti-HBe",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F996389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acyclic nucleotide reverse transcriptase inhibitor (adenosine analog) which interferes with HBV viral RNA dependent DNA polymerase resulting in inhibition of viral replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F996391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic data reported in pediatric patients (12-18 years) similar to reported adult data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.35-0.39 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &le;4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug; rapidly converted to adefovir (active metabolite) in intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7.5 hours; prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Median: 1.75 hours (range: 0.58-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (45% as active metabolite within 24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: ~35% of dose (10 mg) removed during 4 hours hemodialysis session",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F996410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30133?source=see_link\">",
"      see \"Adefovir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not a cure for hepatitis B, nor will it reduce the risk of transmission; appropriate precautions should be maintained to prevent spread to other persons. Frequent blood tests monitoring; follow recommended schedule. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause headache, abdominal pain, diarrhea, or weakness. Report unusual bleeding (blood in urine, tarry stools, or easy bruising), unresolved diarrhea, signs of infection (eg, fever, chills, sore throat, burning urination, flu-like symptoms), persistent fatigue, muscle weakness, or changes in urinary pattern.  Do not stop unless instructed by prescriber; additional monitoring is required after discontinuation to ensure the disease does not recur.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haber BA, Block JM, Jonas MM, et al, \"Recommendations for Screening, Monitoring, and Referral of Pediatric Chronic Hepatitis B,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(5):1007-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10789/abstract-text/19805457/pubmed\" id=\"19805457\" target=\"_blank\">",
"        19805457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jonas MM, Block JM, Haber BA, et al, \"Treatment of Children With Chronic Hepatitis B Virus Infection in the United States: Patient Selection and Therapeutic Options,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2010, 52(6):2192-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10789/abstract-text/20890947/pubmed\" id=\"20890947\" target=\"_blank\">",
"        20890947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jonas MM, Kelly D, Pollack H, et al, \"Safety, Efficacy, and Pharmacokinetics of Adefovir Dipivoxil in Children and Adolescents (Age 2 to &lt;18 Years) With Chronic Hepatitis B,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2008, 47(6):1863-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10789/abstract-text/18433023/pubmed\" id=\"18433023\" target=\"_blank\">",
"        18433023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jonas MM, Kelly D, Pollack H, et al, \"Efficacy and Safety of Long-Term Adefovir Dipivoxil Therapy in Children With Chronic Hepatitis B Infection,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2012, 31(6):578-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10789/abstract-text/22466329/pubmed\" id=\"22466329\" target=\"_blank\">",
"        22466329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, \"Chronic Hepatitis B: Update 2009,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(3):661-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10789/abstract-text/19714720/pubmed\" id=\"19714720\" target=\"_blank\">",
"        19714720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sokal EM, Kelly D, Wirth S, et al, \"The Pharmacokinetics and Safety of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B Virus Infection,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2008, 48(4):512-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10789/abstract-text/18276803/pubmed\" id=\"18276803\" target=\"_blank\">",
"        18276803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86241 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10789=[""].join("\n");
var outline_f10_34_10789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708606\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130623\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663221\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996369\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996398\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130602\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130587\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996404\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996387\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996370\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130645\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996374\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14730090\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996375\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130596\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130598\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996406\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996389\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996391\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F996410\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=related_link\">",
"      Adefovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30133?source=related_link\">",
"      Adefovir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_34_10790="Acute cerebellar ataxia";
var content_f10_34_10790=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute cerebellar ataxia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Mark E Helm, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10790/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/34/10790/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cerebellar ataxia is a syndrome which has been observed following many infectious diseases, including varicella, Epstein-Barr virus, roseola (human herpesvirus 6), enterovirus, rubeola, parvovirus, and mycoplasma infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The syndrome most often is seen in young children with the majority of cases occurring between two and five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,8\">",
"     2,6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, clinical presentation, evaluation, and prognosis of acute cerebellar ataxia will be reviewed here. The differential diagnosis and evaluation of the child presenting with acute ataxia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=see_link\">",
"     \"Approach to the child with acute ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cerebellar ataxia usually occurs in children under six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,8\">",
"     2,6,8",
"    </a>",
"    ]. The true incidence of this disorder is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. In one series, 39 cases requiring hospitalization were reported in an 11-year period from a facility serving a population of roughly 60,000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6\">",
"     6",
"    </a>",
"    ]. A review of acute cerebellar ataxia diagnosed over 24 months in the Netherlands identified an incidence of 0.75 cases per 100,000 individuals under 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/9\">",
"     9",
"    </a>",
"    ]; 70 percent of these cases were treated in hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cerebellar ataxia is typically preceded by an acute febrile illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,10\">",
"     2,6,10",
"    </a>",
"    ]. Varicella is involved in over one-fourth of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Although acute cerebellar ataxia is the most common neurologic complication of varicella infection, it has been estimated that acute cerebellar ataxia occurs in only about 1 in 4000 varicella infections in children younger than 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/1\">",
"     1",
"    </a>",
"    ]. The population study in the Netherlands estimated an even lower rate of 5 cases of acute cerebellar ataxia per 100,000 cases of varicella [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\", section on 'Neurologic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous other infectious agents have been implicated in the pathogenesis of acute cerebellar ataxia, including echovirus, coxsackievirus, Epstein-Barr virus, measles, human herpesvirus 6, mumps, herpes simplex virus I, parvovirus, typhoid fever, malaria, Borrelia burgdorferi (Lyme disease), and mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/7,11-13\">",
"     7,11-13",
"    </a>",
"    ]. More rarely, the syndrome has been reported following vaccination for varicella, hepatitis B and rabies, without evidence of systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,14,15\">",
"     2,6,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of the ataxia has not been established, but emerging evidence suggests that an autoimmune mechanism may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]. Antiviral antibodies and autoreactive antibodies against Purkinje cells, centrosomes, and myelin-associated glycoprotein have been isolated from cerebrospinal fluid in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,4,16-19\">",
"     2,4,16-19",
"    </a>",
"    ]. However, in other case reports, viral nucleic acids have been identified in the cerebrospinal fluid, suggesting that infection of brain tissue may contribute to the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiologic studies in patients with recent onset of acute cerebellar ataxia generally are normal; if lesions are seen, they are usually limited to the cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. Single-photon emission computed tomography has demonstrated diminished perfusion of the cerebellum in patient reports involving children, but not adults, with acute cerebellar ataxia symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cerebellar ataxia is characterized by the acute onset of ataxia four days to three weeks after the inciting illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,11\">",
"     2,6,11",
"    </a>",
"    ]. The symptoms are typically maximal at onset. Gait disturbance is the primary symptom, but the cerebellar dysfunction may be limited to fine motor control problems or tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,4,6\">",
"     2,4,6",
"    </a>",
"    ]. Associated symptoms may include nystagmus (roughly one-half of cases reported), slurred or garbled speech, vomiting, dysarthria, or, in older children, headache [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. Fever, meningismus, and seizures are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute cerebellar ataxia should be directed toward exclusion of other potentially more serious illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. The differential diagnosis includes the following categories (",
"    <a class=\"graphic graphic_table graphicRef79383 \" href=\"UTD.htm?28/9/28830\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,10,16,23-25\">",
"     2,6,10,16,23-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxic &mdash; Ingestion of alcohol or medications (such as anticonvulsant drugs or benzodiazepines), or exposure to toxins including mercury and lead",
"     </li>",
"     <li>",
"      Infectious &mdash; Meningitis, encephalitis, acute disseminated encephalomyelitis, and labyrinthitis",
"     </li>",
"     <li>",
"      Structural &mdash; Head injury, cerebrovascular accident, posterior fossa tumor, and neuroblastoma (with or without associated",
"      <span class=\"nowrap\">",
"       myoclonus/opsoclonus",
"      </span>",
"      syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Metabolic and neurodegenerative &mdash; Metabolic disorders such as abetalipoproteinemia, ornithine transcarbamylase deficiency, and tryptophan malabsorption; or hereditary ataxias such as spinocerebellar ataxias, Friedreich ataxia, or ataxia-telangiectasia. These disorders typically present with gradual onset of ataxia, but symptoms may be intermittent, in contrast to the acute onset in acute cerebellar ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6,16\">",
"       6,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link\">",
"       \"Overview of the hereditary ataxias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A stepwise approach to diagnosis of the child with acute ataxia is described separately (",
"    <a class=\"graphic graphic_algorithm graphicRef77260 \" href=\"UTD.htm?38/11/39090\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=see_link\">",
"     \"Approach to the child with acute ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include questions about antecedent illness, prior vaccinations, head trauma, and potential exposure to intoxicating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6,10,16\">",
"     6,10,16",
"    </a>",
"    ]. The degree of ataxia and gait disturbance varies widely. Mild manifestations may be overlooked by caregivers (leading to under-reporting of the syndrome), but symptoms can be sufficiently severe to lead to an emergency room visit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of altered mental status, fever, meningismus, weakness, focal asymmetric neurologic findings or an insidious onset of ataxia should raise concern for other illnesses in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/6,10,16\">",
"     6,10,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebellar signs in acute cerebellar ataxia include abnormalities in gait (gait ataxia), speech, and coordination of voluntary movement. The range of findings includes the following. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=see_link\">",
"     \"Approach to the child with acute ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gait is typically wide-based, unsteady, lurching, or staggering.",
"     </li>",
"     <li>",
"      Speech abnormalities such as fluctuations in clarity, rhythm, tone, and volume.",
"     </li>",
"     <li>",
"      Difficulty maintaining truncal position (titubation).",
"     </li>",
"     <li>",
"      Impaired coordination of voluntary movements, as demonstrated with over- or under-shooting (best seen on finger-nose testing) and difficulty with rapid alternating movements (dysdiadochokinesia).",
"     </li>",
"     <li>",
"      Hypotonia, tremor, and horizontal nystagmus may also occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other findings may be more suggestive of other diseases. This may be particularly important in those disorders that have effective therapies such as acute disseminated encephalomyelitis or Guillain-Barr&eacute; syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymmetric neurologic deficits are not typical in acute cerebellar ataxia, and may indicate a structural lesion of the central nervous system, stroke or vertebral artery dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/27\">",
"       27",
"      </a>",
"      ], or acute disseminated encephalomyelitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link\">",
"       \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weakness, areflexia, or loss of peripheral sensation associated with the ataxia suggests Guillain-Barr&eacute; syndrome or other sensory ataxia, or acute disseminated encephalomyelitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to the child with acute ataxia\", section on 'Guillain-Barr&eacute; syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurologic evaluation of a child with acute ataxia and the general neurologic examination in children are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the child with acute ataxia\", section on 'Neurologic examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link\">",
"     \"Detailed neurologic assessment of infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation should include toxicology screening including blood alcohol level [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/10\">",
"     10",
"    </a>",
"    ]. When neuroblastoma is suspected clinically, particularly in children presenting with opsoclonus-myoclonus, urinary catecholamines (HVA and VMA) should be measured to screen for the possibility of neuroblastoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the cerebrospinal fluid (CSF) should be performed whenever unusual features such as fever, meningismus, or altered mental status raise concern for CNS infection (meningitis or encephalitis). In the absence of such findings, CSF examination may not be necessary for the emergent evaluation of a child with acute ataxia. Among children with acute cerebellar ataxia, the CSF typically shows a mild lymphocytic pleocytosis with a normal total white cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,10\">",
"     2,6,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with acute cerebellar ataxia, MRI may reveal bilateral diffuse abnormalities of the cerebellar hemispheres, which are not pathognomonic and probably have no prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/28\">",
"     28",
"    </a>",
"    ]. Computerized tomography usually is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,10,20\">",
"     2,6,10,20",
"    </a>",
"    ]. Thus, the main reason to perform brain imaging is to exclude other disorders.",
"   </p>",
"   <p>",
"    Brain imaging is particularly important if the history raises concern about head or neck trauma, if there are signs or symptoms of increased intracranial pressure, if there is concern for a posterior fossa or other intracranial mass, or if the neurologic examination reveals asymmetric focal deficits or other signs suggestive of cerebrovascular accident [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. We also suggest imaging all children with acute ataxia, using magnetic resonance imaging (MRI), unless a clear cause has been established, such as drug intoxication. MRI may reveal the typical findings of acute disseminated encephalomyelitis: focal or multifocal lesions predominantly involving the white matter, without evidence of previous white matter changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cerebellar ataxia typically resolves without sequelae within two to three weeks of presentation, with a median duration of symptoms between 10 and 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Rarely, symptoms persist for several weeks without improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2\">",
"     2",
"    </a>",
"    ]. If worsening of symptoms or relapse occurs, the diagnosis should be reconsidered and other causes of ataxia carefully excluded.",
"   </p>",
"   <p>",
"    There are scattered case reports of treatment of refractory cases with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/29-31\">",
"     29-31",
"    </a>",
"    ] or intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], but these treatments have not been systematically evaluated by randomized trials. When such therapy has been provided, a beneficial response has been noted anecdotally within days.",
"   </p>",
"   <p>",
"    Approximately 10 percent of children with acute cerebellar ataxia have some long-term neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,6,8\">",
"     2,6,8",
"    </a>",
"    ]. Older age at diagnosis and associated Epstein-Barr virus infection appear to confer a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10790/abstract/2,5,16,32,33\">",
"     2,5,16,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cerebellar ataxia is a clinical syndrome characterized by the sudden onset of ataxia, usually manifested as gait disturbance. Most cases occur in toddlers or school-aged children, a few days or weeks after a viral illness, particularly varicella. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of acute cerebellar ataxia has not been fully established, but appears to include autoimmune mechanisms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation is directed to excluding other causes of acute ataxia, including toxic ingestion, head trauma, and infections or structural lesions of the brain. Ataxia also may be caused by metabolic, oncologic, or neurodegenerative processes, which often have gradual or intermittent onset of symptoms (",
"      <a class=\"graphic graphic_table graphicRef79383 \" href=\"UTD.htm?28/9/28830\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=see_link\">",
"       \"Approach to the child with acute ataxia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The history should investigate the possibility of occult toxic exposure or head trauma. The physical examination should assess for unusual signs such as fever, altered mental status, asymmetric focal neurologic deficits, weakness, or areflexia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebrospinal fluid (CSF) should be obtained whenever unusual features such as fever, meningismus, or altered mental status raise concern for CNS infection (meningitis or encephalitis). CSF analysis in acute cerebellar ataxia typically shows a mild lymphocytic pleocytosis with a normal total white cell count. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain imaging should be performed if the history raises concern about head or neck trauma, if there are signs or symptoms of increased intracranial pressure, or if the neurologic examination reveals asymmetric focal deficits. We also suggest imaging all children with acute ataxia, using magnetic resonance imaging (MRI), unless a clear cause has been established such as drug intoxication. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for children with typical features of acute cerebellar ataxia is good. About 90 percent of patients have complete resolution of symptoms within a few weeks, while the remaining 10 percent have some long-term neurologic sequelae. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editorial staff at UpToDate, Inc. would like to recognize Ralph D Feigin, MD, for his contributions to previous versions of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/1\">",
"      Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/2\">",
"      Connolly AM, Dodson WE, Prensky AL, Rust RS. Course and outcome of acute cerebellar ataxia. Ann Neurol 1994; 35:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/3\">",
"      Ito H, Sayama S, Irie S, et al. Antineuronal antibodies in acute cerebellar ataxia following Epstein-Barr virus infection. Neurology 1994; 44:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/4\">",
"      Cohen HA, Ashkenazi A, Nussinovitch M, et al. Mumps-associated acute cerebellar ataxia. Am J Dis Child 1992; 146:930.",
"     </a>",
"    </li>",
"    <li>",
"     Shimizu, Y, Ueno, T, Komatsu, H, et al. Acute cerebellar Ataxia with human parvovirus B19 infection. Arch Dis Child 1999: 80:72.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/6\">",
"      Nussinovitch M, Prais D, Volovitz B, et al. Post-infectious acute cerebellar ataxia in children. Clin Pediatr (Phila) 2003; 42:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/7\">",
"      Hata A, Fujita M, Morishima T, et al. Acute cerebellar ataxia associated with primary human herpesvirus-6 infection: a report of two cases. J Paediatr Child Health 2008; 44:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/8\">",
"      Weiss, S, Carter, S. Course and prognosis of acute cerebellar ataxia in childhood. Neurology 1959; 9:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/9\">",
"      van der Maas NA, Bondt PE, de Melker H, Kemmeren JM. Acute cerebellar ataxia in the Netherlands: a study on the association with vaccinations and varicella zoster infection. Vaccine 2009; 27:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/10\">",
"      Gieron-Korthals MA, Westberry KR, Emmanuel PJ. Acute childhood ataxia: 10-year experience. J Child Neurol 1994; 9:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/11\">",
"      Stumpf DA. Acute ataxia. Pediatr Rev 1987; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/12\">",
"      Ryan MM, Engle EC. Acute ataxia in childhood. J Child Neurol 2003; 18:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/13\">",
"      Lopez MD, Wise C. Acute ataxia in a 4-year-old boy: a case of Lyme disease neuroborreliosis. Am J Emerg Med 2008; 26:1069.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/14\">",
"      Deisenhammer F, Pohl P, B&ouml;sch S, Schmidauer C. Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccine. Acta Neurol Scand 1994; 89:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/15\">",
"      Sunaga Y, Hikima A, Ostuka T, Morikawa A. Acute cerebellar ataxia with abnormal MRI lesions after varicella vaccination. Pediatr Neurol 1995; 13:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/16\">",
"      Davis DP, Marino A. Acute cerebellar ataxia in a toddler: case report and literature review. J Emerg Med 2003; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/17\">",
"      Adams C, Diadori P, Schoenroth L, Fritzler M. Autoantibodies in childhood post-varicella acute cerebellar ataxia. Can J Neurol Sci 2000; 27:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/18\">",
"      Fritzler MJ, Zhang M, Stinton LM, Rattner JB. Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatr 2003; 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/19\">",
"      Shiihara T, Kato M, Konno A, et al. Acute cerebellar ataxia and consecutive cerebellitis produced by glutamate receptor delta2 autoantibody. Brain Dev 2007; 29:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/20\">",
"      Daaboul Y, Vern BA, Blend MJ. Brain SPECT imaging and treatment with IVIg in acute post-infectious cerebellar ataxia: case report. Neurol Res 1998; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/21\">",
"      Go T. Intravenous immunoglobulin therapy for acute cerebellar ataxia. Acta Paediatr 2003; 92:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/22\">",
"      Nagamitsu S, Matsuishi T, Ishibashi M, et al. Decreased cerebellar blood flow in postinfectious acute cerebellar ataxia. J Neurol Neurosurg Psychiatry 1999; 67:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/23\">",
"      Florentine MJ, Sanfilippo DJ 2nd. Elemental mercury poisoning. Clin Pharm 1991; 10:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/24\">",
"      Keller C, Shapira SK, Clark GD. A urea cycle defect presenting as acute cerebellar ataxia in a 3-year-old girl. J Child Neurol 1998; 13:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/25\">",
"      Yabek SM. Meningococcal meningitis presenting as acute cerebellar ataxia. Pediatrics 1973; 52:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/26\">",
"      Yeung WL, Li CK, Nelson EA, et al. Unusual neurological presentation of neuroblastoma. Hong Kong Med J 2003; 9:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/27\">",
"      Papp J, Dorsey ST. A preschool-age child with first-time seizure and ataxia. J Emerg Med 2009; 36:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/28\">",
"      De Bruecker Y, Claus F, Demaerel P, et al. MRI findings in acute cerebellitis. Eur Radiol 2004; 14:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/29\">",
"      Visudtibhan A, Visudhiphan P, Chiemchanya S. Recurrent acute cerebellar ataxia of childhood following nonspecific respiratory tract infection. J Med Assoc Thai 1998; 81:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/30\">",
"      Yazawa S, Ohi T, Sugimoto S, Matsukura S. [A case of acute cerebellar ataxia with abnormal single photon emission computed tomography]. Rinsho Shinkeigaku 1995; 35:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/31\">",
"      G&ouml;hlich-Ratmann G, Wallot M, Baethmann M, et al. Acute cerebellitis with near-fatal cerebellar swelling and benign outcome under conservative treatment with high dose steroids. Eur J Paediatr Neurol 1998; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/32\">",
"      Yamashita S, Murakami C, Izumi Y, et al. Severe chronic active Epstein-Barr virus infection accompanied by virus-associated hemophagocytic syndrome, cerebellar ataxia and encephalitis. Psychiatry Clin Neurosci 1998; 52:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10790/abstract/33\">",
"      Klockgether T, D&ouml;ller G, W&uuml;llner U, et al. Cerebellar encephalitis in adults. J Neurol 1993; 240:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6206 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10790=[""].join("\n");
var outline_f10_34_10790=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6206|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/11/39090\" title=\"algorithm 1\">",
"      Acute ataxia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/9/28830\" title=\"table 1\">",
"      Etiology of ataxia by age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32472?source=related_link\">",
"      Approach to the child with acute ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_34_10791="Hypopigmented sarcoidosis - close view";
var content_f10_34_10791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypopigmented sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented sarcoidosis. Discrete, hypopigmeted macules with central papules are present. The lesions resemble the configuration of a fried egg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10791=[""].join("\n");
var outline_f10_34_10791=null;
var title_f10_34_10792="Oxycodone: Drug information";
var content_f10_34_10792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxycodone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6198?source=see_link\">",
"    see \"Oxycodone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"    see \"Oxycodone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxecta&trade;;",
"     </li>",
"     <li>",
"      OxyCONTIN&reg;;",
"     </li>",
"     <li>",
"      Roxicodone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxycodone CR;",
"     </li>",
"     <li>",
"      CO Oxycodone CR;",
"     </li>",
"     <li>",
"      Oxy.IR&reg;;",
"     </li>",
"     <li>",
"      OxyContin&reg;;",
"     </li>",
"     <li>",
"      OxyNEO&trade;;",
"     </li>",
"     <li>",
"      PMS-Oxycodone;",
"     </li>",
"     <li>",
"      PMS-Oxycodone CR;",
"     </li>",
"     <li>",
"      Supeudol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Management of pain:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Regular or immediate release formulations:",
"     </i>",
"     Initial: 5-15 mg every 4-6 hours as needed; dosing range: 5-20 mg per dose (APS 6th edition). For severe chronic pain, administer on a regularly scheduled basis, every 4-6 hours, at the lowest dose that will achieve adequate analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Controlled release:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     60 mg and 80 mg strengths, a single dose &gt;40 mg, or a total dose of &gt;80 mg daily are for use only in opioid-tolerant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Opioid naive: Initial: 10 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concurrent CNS depressants:  Reduce usual initial oxycodone dose by one-third (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) to one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion from transdermal fentanyl: For each 25 mcg/hour transdermal dose, substitute 10 mg controlled release oxycodone every 12 hours; should be initiated 18 hours after the removal of the transdermal fentanyl patch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Currently on opioids: Use standard conversion chart to convert daily opioid dose to oxycodone equivalent. Initiate controlled release oxycodone with one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) the estimated oxycodone daily dose (mg/day) and provide rescue medication in the form of immediate release oxycodone. Divide the initial controlled release oxycodone daily dose in 2 (for twice-daily dosing, usually every 12 hours) and round down to nearest dosage form.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dose adjustment:",
"     </b>",
"     Doses may be adjusted by changing the total daily dose (not by changing the dosing interval). Doses may be adjusted every 1-2 days and may be increased by 25% to 50%. Dose should be gradually tapered when no longer required in order to prevent withdrawal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Multiplication factors for converting the daily dose of current oral opioid to the daily dose of oral oxycodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Current opioid mg/day dose  x  factor = Oxycodone mg/day dose",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Codeine mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     0.15 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hydrocodone mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     0.9 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hydromorphone mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     4 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Levorphanol mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     7.5 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Meperidine mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     0.1 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Methadone mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     1.5 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Morphine mg/day oral dose",
"     <b>",
"      x",
"     </b>",
"     0.5 = Oxycodone mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Divide the oxycodone mg/day dose into the appropriate dosing interval for the specific form being used.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"      see \"Oxycodone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Management of pain",
"     </b>",
"     (unlabeled use): Immediate release, initial dose: 0.1-0.2 mg/kg/dose (moderate pain) or 0.2 mg/kg/dose (severe pain) (APS 6th edition). For severe chronic pain, administer on a regularly scheduled basis, every 4-6 hours, at the lowest dose that will achieve adequate analgesia.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11347464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentrations are increased ~50% in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute; adjust dose based on clinical situation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F204909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Reduced initial doses may be necessary (use a conservative approach to initial dosing); adjust dose based on clinical situation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Controlled release:",
"     </i>",
"     Decrease initial dose to one-third (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) to one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) the usual starting dose; titrate carefully.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (5 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [concentrate]: 20 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxecta&trade;: 5 mg, 7.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Roxicodone&reg;: 5 mg [DSC], 15 mg, 30 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OxyCONTIN&reg;: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes controlled release tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F204937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, healthcare providers who prescribe OxyContin&reg; need to receive training on the proper use and potential risks of OxyContin&reg;. For training, please refer to file://www.oxycontinrems.com. Prescribers will need retraining every 2 years or following any significant changes to the OxyContin&reg; REMS program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10162706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     OxyContin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289880.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289880.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F204884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Controlled release: Swallow tablet whole. Do not moisten, dissolve, cut, crush, break, or chew controlled release tablets. Controlled release tablets are not indicated for rectal administration; increased risk of adverse events due to better rectal absorption. Controlled release tablets should be administered one at a time and each followed with water immediately after placing in the mouth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release (Oxecta&trade;): Must be swallowed whole with enough water to ensure complete swallowing immediately after placing in the mouth. The tablet should not be wet prior to placing in the mouth. Do not crush, chew, or dissolve the tablets. Do not administer via feeding tubes (eg, gastric, NG) due to potential for obstruction. The formulation uses technology designed to discourage common methods of tampering to prevent misuse/abuse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Appropriate laxatives should be administered to avoid the constipating side effects associated with use. Antiemetics may be needed for persistent nausea.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe pain, normally used in combination with nonopioid analgesics",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     OxyContin&reg; is indicated for around-the-clock management of moderate-to-severe pain when a continuous analgesic is needed for an extended period of time.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       OxyCODONE may be confused with HYDROcodone, OxyCONTIN&reg;, oxymorphone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       OxyCONTIN&reg; may be confused with MS Contin&reg;, oxybutynin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       OxyFast&reg; may be confused with Roxanol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Roxicodone&reg; may be confused with Roxanol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages as reported with OxyContin&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (23%), dizziness (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (23%), nausea (23%), vomiting (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7%), abnormal dreams (1% to 5%), anxiety (1% to 5%), chills (1% to 5%), confusion (1% to 5%), dysphoria (1% to 5%), euphoria (1% to 5%), fever (1% to 5%), insomnia (1% to 5%), nervousness (1% to 5%), thought abnormalities (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (6%), abdominal pain (1% to 5%), anorexia (1% to 5%), diarrhea (1% to 5%), dyspepsia (1% to 5%), gastritis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (6%), twitching (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1% to 5%), hiccups (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, amnesia, anaphylactoid reaction, anaphylaxis, chest pain, dehydration, depression, diverticulitis exacerbation, dysphagia, dysuria, edema, emotional lability, eructation, hallucinations, hematuria, histamine release, hyperalgesia, hyperkinesia, hypoesthesia, hyponatremia, hypotonia, ileus, intestinal obstruction, intracranial pressure increased, malaise, paralytic ileus, paresthesia, seizures, SIADH, speech disorder, ST segment depression, stomatitis, stupor, syncope, tablet in stool (some controlled release dosage forms), tremor, urinary retention, vertigo, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxycodone or any component of the formulation; significant respiratory depression; hypercarbia; acute or severe bronchial asthma; paralytic ileus (known or suspected); GI obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with  hypersensitivity reactions to other phenanthrene-derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenocortical insufficiency: Use with caution in patients with adrenocortical insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; dose adjustment may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal dysfunction; dose adjustment may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Concomitant use with CYP3A4 inhibitors may result in increased effects and potentially fatal respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated or cachectic patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Controlled release tablets: OxyContin&reg; is not intended for use as an &ldquo;as needed&rdquo; analgesic or for the treatment of  mild pain, acute pain, or postoperative pain requiring short-term analgesia (should be used postoperatively only if the patient has received it prior to surgery or if severe, persistent pain is anticipated).",
"     <b>",
"      [U.S. Boxed Warning]: May cause potentially life-threatening respiratory depression even with therapeutic use.  Ensure proper dosing and titration; monitor for respiratory depression especially within the first 24-72 hours of initiation or dose escalation. Oxycodone controlled release tablets should only be prescribed by healthcare professionals familiar with the use of potent opioids for chronic pain. Do NOT crush, break, chew or dissolve controlled release tablets (may result in a potentially fatal overdose);",
"     </b>",
"     60 mg and 80 mg strengths, a single dose &gt;40 mg, or a total dose of &gt;80 mg/day are for use only in opioid-tolerant patients. Tablets may be difficult to swallow and could become lodged in throat; patients with swallowing difficulties may be at increased risk. Cases of intestinal obstruction or diverticulitis exacerbation have also been reported, including cases requiring medical intervention to remove the tablet; patients with an underlying GI disease (eg, esophageal cancer, colon cancer) may be at increased risk.",
"     <b>",
"      [U.S. Boxed Warning]: Accidental exposure may result in fatal overdose of oxycodone, especially in children.",
"     </b>",
"     <b>",
"      [U.S. Boxed Warning]: Healthcare provider should be alert to problems of abuse, misuse, and diversion.   Patients should be assessed for risk of abuse or addiction prior to therapy and all patients should be monitored for signs of misuse, abuse, and addiction. Risk of opioid abuse is increased in patients with a history or family history of alcohol or drug abuse or mental illness.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral solutions:",
"     <b>",
"      [U.S. Boxed Warning]: Highly concentrated oral solution (20 mg/mL) should only be used in opioid tolerant patients (taking &ge;30 mg/day of oxycodone or equivalent for &ge;1 week). [U.S. Boxed Warning]: Orders for oxycodone oral solutions (20 mg/mL or 5 mg/5 mL) should be clearly written to include the intended dose (in mg vs mL) and the intended product concentration to be dispensed to avoid potential dosing errors. Products should be stored out of reach of children; seek immediate medical care in the event of accidental ingestion.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to problems of abuse, misuse, and diversion. Patients should be assessed for risk of abuse or addition prior to therapy and all patients should be monitored for signs of misuse, abuse, and addiction. Abuse of products by crushing, chewing, snorting, or injecting may result in severe overdose, adverse effects, or death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F204899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Opioids cross the placenta; respiratory depression and withdrawal symptoms may occur in the neonate following use during pregnancy. Controlled release formulations should not be used immediately prior to or during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11347295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedation and/or respiratory depression may occur in the infant; symptoms of opioid withdrawal may occur following the cessation of breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F204891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Instruct patient to avoid high-fat meals when taking some products (food has no effect on the reformulated OxyContin&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (OxyCODONE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $79.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (OxyCODONE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (30 mL): $221.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (OxyCODONE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (5 mL): $3.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (OxyCONTIN Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (20): $52.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (20): $78.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (20): $100.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (20): $142.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (20): $178.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (20): $259.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (20): $335.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxecta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $320.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $320.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (OxyCODONE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $47.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $62.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $75.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $110.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $143.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Roxicodone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $175.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $343.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F204881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood level of 5 mg/L associated with fatality",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F204892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Endone (AU);",
"     </li>",
"     <li>",
"      Ircodon (KP);",
"     </li>",
"     <li>",
"      M-Oxy (PE);",
"     </li>",
"     <li>",
"      Oxycod (IL);",
"     </li>",
"     <li>",
"      OxyContin (AR, AT, AU, BR, CH, CL, CN, CO, CR, CZ, DK, EC, EE, ES, FI, GB, GT, HN, IE, IL, IT, MY, NI, NL, NO, NZ, PA, PE, PL, PT, PY, SE, SG, SV, VE);",
"     </li>",
"     <li>",
"      Oxycontin CR (KP);",
"     </li>",
"     <li>",
"      Oxycontin LP (FR);",
"     </li>",
"     <li>",
"      Oxygesic (DE);",
"     </li>",
"     <li>",
"      Oxynorm (AT, AU, BE, CH, DK, ES, FI, FR, GB, MY, NO, NZ, PH, SE, SG);",
"     </li>",
"     <li>",
"      Oxynorm IV (SG);",
"     </li>",
"     <li>",
"      Oxyrapid (EC);",
"     </li>",
"     <li>",
"      Plexicodim (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Pain relief: Immediate release: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Immediate release: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: 3-6 hours; Controlled release: &le;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.6 L/kg; distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatically via CYP3A4 to noroxycodone (has weak analgesic), noroxymorphone, and alpha- and beta-noroxycodol. CYP2D6 mediated metabolism produces oxymorphone (has analgesic activity; low plasma  concentrations), alpha- and beta-oxymorphol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Controlled release, immediate release: 60% to 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: 2-4 hours; controlled release: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Immediate release: 1.2-1.9 hours; Controlled release: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~19% as parent; &gt;64% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10792/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalso E and Vainio A, &ldquo;Morphine and Oxycodone Hydrochloride in the Management of Cancer Pain,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1990, 47(5):639-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10792/abstract-text/2188774/pubmed\" id=\"2188774\" target=\"_blank\">",
"        2188774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10792/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turturro MA and O'Toole KS, &ldquo;Oxycodone-Induced Pulmonary Edema,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1991, 9(2):201-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10792/abstract-text/1994955/pubmed\" id=\"1994955\" target=\"_blank\">",
"        1994955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/34/10792/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9729 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10792=[""].join("\n");
var outline_f10_34_10792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709186\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204904\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204935\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204907\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204921\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204908\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347464\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204909\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204880\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204864\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204937\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234132\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10162706\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204884\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204883\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204933\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204887\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204868\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204929\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204873\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204899\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204875\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204890\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204912\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347295\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204891\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989443\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204877\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204881\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204892\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204867\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204886\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9729|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6198?source=related_link\">",
"      Oxycodone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=related_link\">",
"      Oxycodone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_34_10793="Serologic screening for HIV infection";
var content_f10_34_10793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serologic screening for HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10793/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10793/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10793/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10793/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/34/10793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the mid-1980s, the diagnostic accuracy of HIV infection testing has improved with successive generations of assays. However, many persons remain unaware of their HIV infection, leading to significant morbidity and mortality and the risk of further transmission to others [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/1\">",
"     1",
"    </a>",
"    ]. Earlier diagnosis can decrease the number of individuals who present with advanced immunosuppression and opportunistic infections. Widespread diagnostic testing for HIV can also improve knowledge of the seroprevalence of infection, which is important for the appropriate distribution of services and interventions in resource-limited and resource-rich settings alike [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From 2007 through 2010, a total of 191,697 persons received a diagnosis of HIV in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/3\">",
"     3",
"    </a>",
"    ]. The majority of HIV cases occurred in males (78 percent). The largest number of HIV cases occurred in blacks (48 percent) and 16 percent of all newly diagnosed patients were born outside the United States. This topic will address screening for HIV infection; detailed information about the diagnostic accuracy of the individual tests is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF HIV DIAGNOSTIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both standard and rapid HIV testing assays are available for screening. The sensitivity and specificity of both types of assays are excellent, although both require confirmatory testing. Later generation combination HIV antibody and antigen assays are also available. The advantage of these combination assays is their ability to detect HIV p24 antigen during acute infection when antibody formation may not yet be detected (eg, \"window period of acute HIV infection\").",
"   </p>",
"   <p>",
"    A concise summary of these diagnostic assays is found below; detailed information regarding the diagnostic accuracy and interpretation of HIV testing is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Standard testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard testing includes a screening enzyme immunoassay (EIA) followed by a confirmatory Western blot (WB) if the initial EIA is positive. A confirmatory Western blot is performed to exclude the possibility of a false positive EIA test. Such testing requires that the patient return for follow-up because of the time required for EIA testing.",
"   </p>",
"   <p>",
"    The accuracy of standard HIV serologic testing is extremely high (&gt;99 percent sensitivity and specificity). The results are reported as positive, negative, or indeterminate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rapid HIV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid HIV testing has the advantage of offering preliminary test results at the same patient encounter. This is particularly useful in patients who obtain sporadic medical care.",
"   </p>",
"   <p>",
"    The results are reported as positive, negative, or indeterminate. The accuracy of rapid testing is high (&gt;99 percent sensitivity and specificity). However, a positive rapid test is only preliminary and must be confirmed with standard antibody testing before a diagnosis of HIV infection can be established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing is complete if the rapid test is negative, unless there is clinical suspicion of acute HIV infection. In this scenario, testing for HIV p24 antigen or HIV RNA is also indicated since HIV antibodies may not yet be detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnostic assays for HIV infection\", section on 'Rapid antibody tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid testing has also been approved by the US Food and Drug Administration (FDA) for use at home with OraQuick, a product of OraSure Technologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnostic assays for HIV infection\", section on 'In-home HIV screening tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combination HIV antibody and antigen testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fourth generation HIV tests are distinguished from the antibody tests above by their ability to detect both antibody and HIV p24 antigen. These diagnostic assays have excellent sensitivity and specificity for chronic infection. The additional advantage of these assays is in their ability to detect HIV p24 antigen during acute infection when antibody formation may not yet be detected (eg, \"window period of acute HIV infection\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnostic assays for HIV infection\", section on 'Combined antibody antigen tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DELAYED DIAGNOSIS OF HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated number of people &gt;13 years old living with HIV infection in the United States at the end of 2006 was 1,100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/4\">",
"     4",
"    </a>",
"    ]. Of these, an estimated 252,000 to 312,000 persons are unaware of their infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Undiagnosed HIV infection can lead to significant morbidity and mortality and an increased risk of transmission to others. Clinical trials have shown and meta-analyses have confirmed that potent ART improves survival and reduces AIDS-related complications in patients with advanced HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/7\">",
"     7",
"    </a>",
"    ]. The impact of late diagnosis on morbidity and mortality is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) has estimated that the detection of HIV infection, in those unaware of their infection, would also result in a decrease in 32,000 new infections each year, a reduction of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 32 percent of patients receive their first HIV diagnostic test within one year of an AIDS-defining illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/9\">",
"     9",
"    </a>",
"    ]. Given the natural history of HIV infection, this implies that the average patient had HIV for approximately seven years before the first serologic test [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/10\">",
"     10",
"    </a>",
"    ]. A review of 1302 \"late testers\" (patients with an AIDS diagnosis within one year of the first positive test) demonstrated that these patients had a total of 7988 encounters with the health care system from 1997 to 2005 without HIV testing, an average of 6.5",
"    <span class=\"nowrap\">",
"     visits/patient.",
"    </span>",
"    These encounters were viewed as \"missed opportunities\" since early detection is important for both individual health and public health. Another study demonstrated that late initiation of ART was found to be more prevalent among black and Hispanic individuals than white individuals with disproportionately higher associated morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CDC National HIV Surveillance System found that between 2006 and 2009 there were an estimated 125,104 new diagnoses of HIV infection. For those with a detailed testing history, 41 percent were diagnosed on their first test, while 59 percent were diagnosed with HIV within one to two years after a negative test result [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/12\">",
"     12",
"    </a>",
"    ]. These data point to the importance of repeat testing among those at ongoing risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF RISK-BASED SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, public health authorities were reluctant to advise routine HIV testing because earlier-generation HIV assays were associated with high rates of false positive results in low-risk populations. Thus, prior to 2006, US-based HIV testing algorithms were based on risk.",
"   </p>",
"   <p>",
"    However, risk-based testing failed to identify a substantial proportion of people with HIV infection, since many patients do not declare risk or do not consider themselves at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/13\">",
"     13",
"    </a>",
"    ]. Also, HIV testing can be associated with stigma, which can lead to test avoidance. Requirements mandating counseling and consent have been shown to be significant barriers to testing. Finally, prior testing strategies failed to reduce the number of new HIV infections, which are estimated at approximately",
"    <span class=\"nowrap\">",
"     56,000/year",
"    </span>",
"    in the US every year since 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RATIONALE FOR ROUTINE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The movement towards universal HIV screening was heavily influenced by the success of this intervention in other patient populations. Since 1995, HIV screening has been routinely advocated in all pregnant women by the Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists. This intervention has been highly effective and well accepted by patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/14\">",
"     14",
"    </a>",
"    ]. The success of screening in this patient population, coupled with improvements in testing, treatment, and retention in care, have led to alternative recommendations for HIV screening in all adults and adolescents, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are important differences between HIV testing in the present era compared with 1985, which provided the rationale for general screening after 2006:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV testing has improved dramatically; serologic testing has a sensitivity and specificity of greater than 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The introduction of rapid HIV testing has made screening for HIV remarkably simple and fast [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional rationale for HIV screening includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A generic approach to HIV testing reduces stigma, because this strategy is applied to all patients and not only to those considered at high risk",
"     </li>",
"     <li>",
"      Diagnosis often leads to treatment with highly effective antiretroviral therapy, which reduces the risk of morbidity and mortality for the patient and the risk of HIV transmission. [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/7,18,19\">",
"       7,18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early HIV diagnosis allows the implementation of other effective interventions, such as immunizations and prophylaxis against opportunistic infections [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Knowledge of one's HIV seropositive status may lead to modification of risk behaviors, which is an important public health benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple studies indicate routine HIV testing is cost effective if the seroprevalence is &ge;0.1 percent (which is well below the national average of 0.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/20-23\">",
"       20-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential harms of universal screening include the emotional impact of a false positive test. If the patient is discharged from the hospital before the confirmatory test results are reported, the patient needs to understand that this diagnosis is not established until the results of the Western blot are reported. However, the sensitivity and specificity of rapid testing has improved significantly over recent years, decreasing the risk of an inaccurate diagnosis. Furthermore, expanded HIV testing has been shown to yield a favorable return on public health investment, even in low prevalence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS BY EXPERT GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006, the CDC issued revised guidelines for HIV testing in adolescents and adults in healthcare settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"     25",
"    </a>",
"    ]. These guidelines advocate routine voluntary HIV screening of all patients aged 13 to 64 years as a normal part of medical care, similar to screening for other treatable diseases, and without the prior requirement for signed consent or counseling.",
"   </p>",
"   <p>",
"    In 2012, the United States Preventive Services Task Force (USPSTF) released preliminary recommendations for universal HIV screening among patients aged 15 to 65 years, replacing its previous endorsement for risk-based screening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/26\">",
"     26",
"    </a>",
"    ]. This update was based on the growing evidence that antiretroviral therapy can reduce the risk of sexual transmission of HIV and reduce morbidity and mortality in all HIV-infected patients, including those who may be asymptomatic and only identified through screening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Physicians (ACP) Guidance Statement on HIV screening, released in 2009, similarly endorsed universal screening, although suggested that the age range be expanded to 75 years, due to the growing number of HIV infections in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many authorities still consider counseling an integral component to testing in order to reduce HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The CDC has maintained the position that counseling should be neither discouraged nor mandated, since this legal requirement can serve as a barrier to testing. They advocate counseling for HIV-infected persons in a fashion analogous to counseling patients with other sexually transmitted infections, such as gonorrhea or chlamydia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534859744\">",
"    <span class=\"h2\">",
"     Resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007, the World Health Organization (WHO) and UNAIDS (The United Nations Joint Programme on",
"    <span class=\"nowrap\">",
"     HIV/AIDS)",
"    </span>",
"    also issued recommendations for wider HIV testing in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/31\">",
"     31",
"    </a>",
"    ]. The guidelines recognize that the former model for HIV screening has been client-initiated testing, which has been limited by stigma, discrimination, and unrecognized personal risk, even in endemic areas.",
"   </p>",
"   <p>",
"    The 2007 guidelines have changed the focus to provider-initiated testing and counseling for patients in health care facilities, particularly those who present with symptoms consistent with HIV infection. In endemic areas, HIV testing should be recommended whether or not the patient has symptoms consistent with HIV disease. In areas with lower endemicity, testing should be offered in health care facilities considered to have high HIV prevalence (eg, tuberculosis and STD clinics).",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     WHO/UNAIDS",
"    </span>",
"    mandates that all testing must be voluntary, confidential, and done with the patient's consent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534859883\">",
"    <span class=\"h1\">",
"     IMPLEMENTATION OF ROUTINE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Opt-out testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine testing is implemented through a strategy called \"opt-out testing\", whereby the patient is informed orally, or in writing, that HIV testing will be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"     25",
"    </a>",
"    ]. The patient may elect to decline or defer testing; agreement to testing is inferred by the consent for care form that is standard for all health care facilities.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) also recommends the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening should be voluntary and undertaken only with the patient's knowledge and understanding that HIV testing is being planned.",
"     </li>",
"     <li>",
"      Patients should be offered an opportunity to ask questions prior to testing; however, a separate consent form for HIV testing is no longer recommended.",
"     </li>",
"     <li>",
"      Interpreter services or translated materials must be available for patients with limited English proficiency.",
"     </li>",
"     <li>",
"      If a patient declines HIV testing, this decision should be documented in the patient's medical chart.",
"     </li>",
"     <li>",
"      Testing is encouraged in all healthcare settings: in-patient admissions, emergency rooms, and medical, STD, and family planning clinics.",
"     </li>",
"     <li>",
"      Patients who test positive should be informed of this result and be referred for longitudinal HIV care. The interpretation of positive, negative, and indeterminate test results is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of \"opt-out\" testing is routinely done in the United Kingdom; one study demonstrated that this approach led to an increased percentage of individuals being tested (from 35 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/32\">",
"     32",
"    </a>",
"    ]. The CDC estimates that the percentage of persons aged 18 to 64 years who were ever tested for HIV infection has increased from 40 percent from 2001 to 2006 to 45 percent in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Consent for testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the CDC 2006 guidelines, a separate written consent for HIV testing should no longer be required in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this may not apply in certain states that have legislation that requires written consent, often with required pretest and posttest counseling. Ten states that still require specific written consent include Alabama, Connecticut, Hawaii, Massachusetts, New York, Michigan, Pennsylvania, Rhode Island, Wisconsin, and Nebraska [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. Several other states still have laws requiring counseling (ie, Connecticut, Delaware, Florida, Indiana, Montana, Ohio, and West Virginia) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/33\">",
"     33",
"    </a>",
"    ]. Specific state information can also be obtained on the National Association of State and Territorial AIDS Directors (NASTAD) website at:",
"    <a class=\"external\" href=\"file://www.nastad.org/\">",
"     file://www.nastad.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Even in the spirit of \"opt-out\" testing, the patient should still be informed, either orally or in writing, that HIV testing will be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"     25",
"    </a>",
"    ]. The patient may elect to decline or defer testing; agreement to testing is inferred unless the patient specifically declines. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Opt-out testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FREQUENCY OF TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of testing is arbitrary; one-time testing is reasonable in low-risk patients. &nbsp;However, repeat testing should be offered when there is a new risk, such as unprotected sex with a new partner.",
"   </p>",
"   <p>",
"    Annual or more frequent testing is recommended for high-risk persons including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Injection-drug users and their sex partners",
"     </li>",
"     <li>",
"      Persons who exchange sex for money or drugs",
"     </li>",
"     <li>",
"      Sex partners of HIV-infected persons",
"     </li>",
"     <li>",
"      Men who have sex with men (MSM) or heterosexual persons who themselves, or whose sex partners, have had other partners since their most recent HIV test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Areas with an established prevalence of &lt;0.1 percent are exempted from this recommendation. The ACP recommends that prevalence data for a hospital, clinic, or region should be based on tests of &gt;4000 tested persons to be considered generally representative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing of HIV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine HIV testing should be performed at the time of the initial medical clinic visit. If a specific exposure has occurred (eg, unprotected sex with a new partner), baseline antibody testing should be obtained with repeat testing at 6, 12 and 24 weeks analogous to testing of exposed health care workers.",
"   </p>",
"   <p>",
"    If the patient has possible symptoms of primary HIV infection, viral load testing should be performed in addition to antibody testing. Caution is advised with HIV viral loads &lt;10,000",
"    <span class=\"nowrap\">",
"     c/mL",
"    </span>",
"    in the absence of confirmed positive serology, since 2 to 9 percent of patients without HIV infection will have a false positive HIV RNA test with low levels of viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link&amp;anchor=H18410709#H18410709\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER SCENARIOS FOR HIV TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion above focuses on universal screening for HIV infection. There are also various situations where targeted HIV testing may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patients with suspected HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV testing should be offered to patients with signs or symptoms consistent with chronic HIV infection. Clues to the possible diagnosis of HIV infection include the following signs and symptoms (if found without an alternative explanation):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thrush",
"     </li>",
"     <li>",
"      Unexplained weight loss or fevers",
"     </li>",
"     <li>",
"      Unexplained dementia",
"     </li>",
"     <li>",
"      Generalized lymphadenopathy",
"     </li>",
"     <li>",
"      Aseptic meningitis",
"     </li>",
"     <li>",
"      Peripheral neuropathy",
"     </li>",
"     <li>",
"      Herpes zoster (if disseminated or involves more than one non-adjacent dermatome)",
"     </li>",
"     <li>",
"      Oral hairy leukoplakia",
"     </li>",
"     <li>",
"      Opportunistic infections suggesting defective cell-mediated immunity",
"     </li>",
"     <li>",
"      Kaposi's sarcoma",
"     </li>",
"     <li>",
"      B cell lymphoma, especially if extranodal and aggressive",
"     </li>",
"     <li>",
"      Unexplained cytopenias",
"     </li>",
"     <li>",
"      New onset seborrheic dermatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Occupational exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any person whose blood or body fluid is the source for an occupational exposure should be informed of the incident and tested for HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"     25",
"    </a>",
"    ]. Rapid HIV testing can eliminate the need for postexposure prophylaxis for the exposed health care provider. The source of the injury should be informed that the test is being done; however, state laws vary in allowance for testing in patients who are unable to give informed consent in the context of healthcare worker exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Blood or organ donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;All donors of blood, bone marrow, semen, or organs undergo mandatory HIV testing. Blood donations are screened serologically and with nucleic acid amplification testing, which can detect HIV RNA at a minimum concentration of approximately 5.5",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p>",
"    The risk of transmission of HIV through blood transfusion is estimated to be 1 in 1.5 million [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/35\">",
"     35",
"    </a>",
"    ]. A report of the first case of HIV transmission through a blood transfusion since 2002 was documented in a lookback investigation of a repeat blood donor who became HIV seropositive between serial donations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/36\">",
"     36",
"    </a>",
"    ]. One recipient, who was a renal transplant patient, had acquired HIV infection without any other risk factors; DNA from the donor and recipient demonstrated that the viral sequences shared 99 percent homology.",
"   </p>",
"   <p>",
"    Although the risk of HIV transmission through blood is extremely rare, transfusion should be considered in a patient who has no identifiable risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Confirmation of HIV status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home HIV tests, anonymous tests, and other test results that cannot be confirmed by medical documentation should be repeated using standard serologic methods since results of these tests may be misleading.",
"   </p>",
"   <p>",
"    Occasional patients report factitious HIV infection, emphasizing the need to confirm a patient's HIV status as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=see_link\">",
"     \"Primary care of HIV-infected adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pregnant women should undergo HIV screening early in each pregnancy, with repeat testing in the third trimester for those at high risk of infection or in high-prevalence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/25,26,38,39\">",
"     25,26,38,39",
"    </a>",
"    ]. Women who present in labor without prior HIV testing should undergo rapid HIV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. While awaiting confirmatory testing, a pregnant woman with a positive rapid HIV test should be managed as if HIV-infected with prophylaxis to prevent perinatal HIV transmission, according to standard guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Critical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV testing in the setting of critical illness is a particularly controversial area in states that require signed consent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/43\">",
"     43",
"    </a>",
"    ]. Some have argued strongly for modifications in state laws to allow HIV testing in critically ill patients who are unable to consent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Six states allow testing for HIV without consent in the setting of a \"life-threatening\" situation; 13 states require consent unless physicians believe the test results will affect the clinical care of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/43\">",
"     43",
"    </a>",
"    ]. Others permit a surrogate to consent on the patient's behalf [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/44\">",
"     44",
"    </a>",
"    ]. The American Medical Association and British General Medical Council support nonconsented HIV testing in this setting as well. However, nonconsented HIV testing is rarely done and there is lack of legal precedent.",
"   </p>",
"   <p>",
"    In cases where HIV testing cannot be performed, CD4 cell counts or HIV viral load testing should never be used to infer HIV status to bypass laws requiring signed consent or counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/44\">",
"     44",
"    </a>",
"    ]; this action may be in violation of legal statutes in some states. Furthermore, this action is ill advised from a clinical standpoint since CD4 cell counts can be markedly depressed in the setting of certain conditions unrelated to HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PATIENT-RELATED ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled regarding harm reduction, such as clean needle use by injection drug users, or use of barrier protection in those who have multiple sex partners. HIV-infected patients receiving antiretroviral agents need to know that achievement of \"no detectable virus\" reduces the risk of HIV transmission but does not eliminate this risk.",
"   </p>",
"   <p>",
"    Testing for other sexually transmitted diseases should be performed, and immunizations against other pathogens, such as hepatitis B, should also be offered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persons with an indeterminate or positive screening HIV test need to be counseled that additional testing is required; however, in the interim precautions should be taken to decrease transmission to others. Follow-up testing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Patient confidentiality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respect for patient confidentiality is necessary to minimize discrimination in insurance, employment, health care, and personal relationships encountered by HIV-positive individuals.",
"   </p>",
"   <p>",
"    Institution of routine HIV screening programs must be accompanied by scrupulous attention to patient confidentiality and appropriate counseling for post-test results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Patient acceptance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acceptability of HIV testing varies widely depending upon various factors. Higher acceptance rates were found in high-prevalence areas, assurance of confidentiality protections, and the provider's belief that the test results would be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/13,46\">",
"     13,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may have HIV testing on oral fluids, whole blood through venipuncture, or via fingerstick testing. One study evaluated whether offering HIV screening within an emergency room setting with oral fluid sampling or fingerstick testing would have an effect on rates of participation; however, acceptance of screening was similar (62 versus 59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No clinical trials have evaluated the acceptability of alternative testing with rapid tests or home testing kits although there is increasing enthusiasm for home testing by consumers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/13,48\">",
"     13,48",
"    </a>",
"    ]. Currently available home tests require laboratory processing in a reference lab and results are reported with a counseling message [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Referral to care",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient is diagnosed with HIV infection, it is critically important to refer the patient for appropriate medical care. One study used routine surveillance data to measure time to initiation of care in New York City residents who were diagnosed with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/50\">",
"     50",
"    </a>",
"    ]. Of 1928 patients, 64 percent initiated care within three months, 19 percent initiated care later than three months, and 17 percent never had follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PHYSICIAN-RELATED ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about provider perspectives on routine HIV testing. One study that examined physician attitudes found that barriers to opt-out testing included concerns about time constraints and the potential negative impact on the patient-provider relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four studies using mathematical modeling techniques have demonstrated the cost-effectiveness of routine screening for HIV infection in the era of potent antiretroviral therapy that is comparable to other accepted standards for clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/20-22,52\">",
"     20-22,52",
"    </a>",
"    ]. In one study, the cost-effectiveness of one-time screening remained below",
"    <span class=\"nowrap\">",
"     $50,000/quality-adjusted",
"    </span>",
"    life-year (QALY) in settings where HIV prevalence was as low as 0.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/23\">",
"     23",
"    </a>",
"    ]. This model includes pretest counseling, which costs three times more than rapid HIV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/53\">",
"     53",
"    </a>",
"    ]. Another model, which included one-time HIV screening of low-risk persons coupled with annual screening of high-risk persons, estimated that 6.7 percent of new HIV infections could be prevented in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/52\">",
"     52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MONITORING PROGRESS OF HIV SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have attempted to evaluate the progress of opt-out HIV screening strategies by measuring goals such as increased testing, earlier diagnosis, entry into the medical care system, and decreased HIV incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated non-targeted opt-out HIV screening and physician-directed HIV testing, alternating in sequential four-month time intervals, in an urban emergency room setting in Colorado [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/54\">",
"     54",
"    </a>",
"    ]. Of the 28,043 patients in the opt-out phase who were offered rapid HIV testing, 24 percent did not opt-out. Of the 6702 patients screened, 16 (0.24 percent) were found to be HIV-seropositive and 10 of these were new HIV diagnoses. Of the 29,925 patients included in the physician-directed testing phase, 243 patients (0.8 percent) underwent testing and of these, 5 (2.1 percent) were confirmed to be HIV-infected; 4 of 5 were new HIV diagnoses. The median CD4 cell counts for those with new HIV diagnoses in the opt-out phase and the diagnostic phase were very low (69",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and 13",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    respectively). &nbsp;",
"   </p>",
"   <p>",
"    These results suggest that nontargeted opt-out rapid HIV screening in the emergency department is associated with a modest increase in new HIV diagnoses. No data were available regarding the specific reasons that patients opted out of HIV testing (ie, 76 percent of those offered non-targeted testing). Whether non-targeted opt-out screening would have a greater impact in the context of a continuity clinic, where doctor-patient relationships are already established, is unclear.",
"   </p>",
"   <p>",
"    Other experts have suggested that routine opt-out testing should be considered among patients with a new diagnosis of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/55\">",
"     55",
"    </a>",
"    ], since several epidemiologic studies demonstrate an increased incidence of non-AIDS cancers in patients with HIV infection compared with the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Use of rapid testing in resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to WHO guidelines, rapid tests are considered standard for HIV testing in developing countries, where HIV seroprevalence rates are high [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/2\">",
"     2",
"    </a>",
"    ]. Rapid HIV tests are point-of-care tests that are particularly effective in the field, when laboratory access is limited. Such tests allow the use of saliva or a simple fingerstick, rather than requiring venipuncture.",
"   </p>",
"   <p>",
"    Two rapid tests are recommended by the WHO with the second assay from a different commercial source acting as a confirmatory test; this strategy contrasts with resource-rich settings where standard serologic testing is recommended as the confirmatory test. The advantage of the double rapid test method used in resource-limited countries is that the patient has a definitive answer in one visit.",
"   </p>",
"   <p>",
"    HIV testing is routinely done in pregnant women, hospitalized patients, and patients with tuberculosis in an increasing number of resource-limited countries; in one study of more than 1800 randomly selected community patients in Kenya, 15 percent were diagnosed with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/56\">",
"     56",
"    </a>",
"    ]. In Uganda, where routine testing of hospitalized patients has been implemented, 95 percent of patients have agreed to be tested and 50 percent have been identified as being HIV-seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10793/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in most areas of the developing world &gt;90 percent of persons with HIV have never been tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"       \"Patient information: Testing for HIV (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"       \"Patient information: Symptoms of HIV infection (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both standard HIV assays (ie, enzyme immunoassays) and rapid HIV testing are available for serologic screening. The sensitivity and specificity of both types of assays are excellent, although both require confirmatory testing. Later generation combination HIV antibody and antigen assays are also available. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Delayed diagnosis of HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 40 percent of patients receive their first HIV diagnostic test within one year of an AIDS-defining illness. Late diagnosis thwarts effective interventions, such as immunization, antiretroviral therapy, and prophylaxis against opportunistic infections. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Delayed diagnosis of HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk-based testing failed to identify a substantial proportion of people with HIV, since many patients do not declare risk or do not consider themselves at risk. The movement towards universal HIV screening was heavily influenced by the success of this intervention in other patient populations, such as pregnant women. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Limitations of risk-based screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale for routine HIV testing includes diagnostic accuracy of available assays, favorable cost-effectiveness analyses, and potential behavioral and treatment interventions that favorably impact individual and public health. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Rationale for routine testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening identifies patients with HIV who are likely to benefit from immunization, antiretroviral therapy, and prophylaxis against opportunistic infections. We suggest universal screening of individuals 13 to 75 years of age, as advised by the American College of Physicians, instead of targeted screening based upon risk factors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recommendations by expert groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with signs or symptoms consistent with chronic HIV infection should be offered diagnostic serologic testing. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients with suspected HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The World Health Organization (WHO) and UNAIDS recommend provider-initiated testing and counseling for patients in health care facilities, particularly those who present with symptoms consistent with HIV infection. In areas of high endemicity, HIV testing is recommended regardless of the presence or absence of symptoms. (See",
"      <a class=\"local\" href=\"#H534859744\">",
"       'Resource-limited settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected acute HIV infection need testing for HIV antigen as well as antibody. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"       \"Acute and early HIV infection: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/1\">",
"      Bartlett JG, Branson BM, Fenton K, et al. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA 2008; 300:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/2\">",
"      De Cock KM, Bunnell R, Mermin J. Unfinished business--expanding HIV testing in developing countries. N Engl J Med 2006; 354:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/3\">",
"      Prosser AT, Tang T, Hall HI. HIV in persons born outside the United States, 2007-2010. JAMA 2012; 308:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). HIV prevalence estimates--United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/AIDS--United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/6\">",
"      Berrios DC, Hearst N, Coates TJ, et al. HIV antibody testing among those at risk for infection. The National AIDS Behavioral Surveys. JAMA 1993; 270:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/7\">",
"      Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/8\">",
"      Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: HIV testing and diagnosis among adults--United States, 2001-2009. MMWR Morb Mortal Wkly Rep 2010; 59:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/10\">",
"      Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/11\">",
"      Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Previous HIV testing among adults and adolescents newly diagnosed with HIV infection - National HIV Surveillance System, 18 jurisdictions, United States, 2006-2009. MMWR Morb Mortal Wkly Rep 2012; 61:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/13\">",
"      Chou R, Huffman LH, Fu R, et al. Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/14\">",
"      Voluntary HIV Counseling and Testing of Pregnant Women -- An Assessment of Compliance With Michigan Public Health Statutes. Med Gen Med 2004; 6:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/15\">",
"      Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS 2010; 24:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/16\">",
"      Kleinman S, Busch MP, Hall L, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA 1998; 280:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/17\">",
"      Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis 2007; 45 Suppl 4:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/18\">",
"      Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/19\">",
"      Mayer KH, Krakower D. Antiretroviral medication and HIV prevention: new steps forward and new questions. Ann Intern Med 2012; 156:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/20\">",
"      Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med 2005; 352:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/21\">",
"      Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/22\">",
"      Walensky RP, Weinstein MC, Kimmel AD, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med 2005; 118:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/23\">",
"      Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/24\">",
"      Hutchinson AB, Farnham PG, Duffy N, et al. Return on public health investment: CDC's Expanded HIV Testing Initiative. J Acquir Immune Defic Syndr 2012; 59:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/25\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement DRAFT, November 2012. file://www.uspreventiveservicestaskforce.org/draftrec.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/27\">",
"      Chou R, Selph S, Dana T, et al. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 157:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/28\">",
"      Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med 2009; 150:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/29\">",
"      Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998; 280:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/30\">",
"      Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. Am J Public Health 1999; 89:1397.",
"     </a>",
"    </li>",
"    <li>",
"     WHO/UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva, Switzerland: World Health Organization (WHO), 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/32\">",
"      Stanley B, Fraser J, Cox NH. Uptake of HIV screening in genitourinary medicine after change to \"opt-out\" consent. BMJ 2003; 326:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/33\">",
"      Mahajan AP, Stemple L, Shapiro MF, et al. Consistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings. Ann Intern Med 2009; 150:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/34\">",
"      Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/biologicsbloodvaccines/guidancecompliance regulatoryinformation/guidances/blood/ucm073445.htm (Accessed on January 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). HIV transmission through transfusion --- Missouri and Colorado, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/37\">",
"      Craven DE, Steger KA, La Chapelle R, Allen DM. Factitious HIV infection: the importance of documenting infection. Ann Intern Med 1994; 121:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/38\">",
"      American College of Obstetrics and Gynecology Committee on Obstetric Practice. ACOG Committee Opinion No. 418: Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2008; 112:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/39\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/40\">",
"      Kallenborn JC, Price TG, Carrico R, Davidson AB. Emergency department management of occupational exposures: cost analysis of rapid HIV test. Infect Control Hosp Epidemiol 2001; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/41\">",
"      Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004; 292:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/42\">",
"      Rahangdale L, Cohan D. Rapid human immunodeficiency virus testing on labor and delivery. Obstet Gynecol 2008; 112:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/43\">",
"      Halpern SD. HIV testing without consent in critically ill patients. JAMA 2005; 294:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/44\">",
"      Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med 2006; 355:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/45\">",
"      Bozzette SA. Routine screening for HIV infection--timely and cost-effective. N Engl J Med 2005; 352:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/46\">",
"      Irwin KL, Valdiserri RO, Holmberg SD. The acceptability of voluntary HIV antibody testing in the United States: a decade of lessons learned. AIDS 1996; 10:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/47\">",
"      White DA, Scribner AN, Huang JV. A comparison of patient acceptance of fingerstick whole blood and oral fluid rapid HIV screening in an emergency department. J Acquir Immune Defic Syndr 2009; 52:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/48\">",
"      Wright AA, Katz IT. Home testing for HIV. N Engl J Med 2006; 354:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/49\">",
"      Branson BM. Home sample collection tests for HIV infection. JAMA 1998; 280:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/50\">",
"      Torian LV, Wiewel EW, Liu KL, et al. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 2008; 168:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/51\">",
"      Bokhour BG, Solomon JL, Knapp H, et al. Barriers and facilitators to routine HIV testing in VA primary care. J Gen Intern Med 2009; 24:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/52\">",
"      Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 2010; 153:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/53\">",
"      Branson BM. To screen or not to screen: is that really the question? Ann Intern Med 2006; 145:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/54\">",
"      Haukoos JS, Hopkins E, Conroy AA, et al. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 2010; 304:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/55\">",
"      Chiao EY, Dezube BJ, Krown SE, et al. Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010; 304:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10793/abstract/56\">",
"      Amornkul PN, Vandenhoudt H, Nasokho P, et al. HIV prevalence and associated risk factors among individuals aged 13-34 years in Rural Western Kenya. PLoS One 2009; 4:e6470.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3736 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.96.59.103-A977B79397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10793=[""].join("\n");
var outline_f10_34_10793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF HIV DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Standard testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rapid HIV testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combination HIV antibody and antigen testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DELAYED DIAGNOSIS OF HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LIMITATIONS OF RISK-BASED SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RATIONALE FOR ROUTINE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECOMMENDATIONS BY EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H534859744\">",
"      Resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H534859883\">",
"      IMPLEMENTATION OF ROUTINE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Opt-out testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Consent for testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FREQUENCY OF TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing of HIV testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER SCENARIOS FOR HIV TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patients with suspected HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Occupational exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Blood or organ donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Confirmation of HIV status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PATIENT-RELATED ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Patient confidentiality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Patient acceptance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Referral to care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PHYSICIAN-RELATED ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COST-EFFECTIVENESS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MONITORING PROGRESS OF HIV SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Use of rapid testing in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=related_link\">",
"      Acute and early HIV infection: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=related_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=related_link\">",
"      Primary care of HIV-infected adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_34_10794="Adverse effects of antiretroviral therapy in developing countries";
var content_f10_34_10794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adverse effects of antiretroviral therapy in developing countries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Douglas Krakower, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Babafemi Taiwo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Robert L Murphy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Rajesh T Gandhi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10794/contributors\">",
"     John A Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/34/10794/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/34/10794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe and effective management of HIV infection requires an understanding of the adverse effects associated with antiretroviral therapy (ART). Drug-related symptoms decrease adherence, which negatively impacts virologic suppression and immunologic recovery in a disease that requires lifelong therapy. Special considerations in drug-related toxicity have been observed in the years since the beginning of the ART \"roll-out\" in resource-limited settings.",
"   </p>",
"   <p>",
"    This topic will address specific issues in the treatment of HIV-infected patients in resource-limited settings. Further information regarding the epidemiology of the global HIV epidemic and treatment programs is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPECIAL TREATMENT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several problems that are unique to resource-limited settings that contribute to risk of drug toxicity, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cost considerations in formulary selections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens in resource-limited settings frequently contain older antiretrovirals that are more likely to have adverse effects than newer, more expensive agents. The most common first-line regimens employed in resource-limited settings are either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and a non-nucleoside reverse transcriptase inhibitor, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . World Health Organization (WHO) guidelines serve as an important reference in resource-limited areas and exert a strong influence over formulary selections, leading to the use of antiretroviral agents that may no longer be considered first-line in resource-rich settings due to known toxicities. For example, zidovudine remains on the WHO list of first-line agents despite frequent adverse effects because it costs less than newer agents like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    . However, based on clinical trials data demonstrating more severe toxicities with the use of stavudine, the WHO removed this agent from its list of first-line agents, a development that is likely to have a significant impact on formulary selections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. When stavudine is used, the WHO recommends reducing the dose in adults to 30 mg twice a day, regardless of body weight in an effort to reduce adverse events (",
"    <a class=\"external\" href=\"file://www.who.int/hiv/art/ARTadultsaddendum.pdf\">",
"     file://www.who.int/hiv/art/ARTadultsaddendum.pdf",
"    </a>",
"    ). The cost-effectiveness of using newer agents as first-line therapy to avoid toxicities is under investigation, and is expected to influence formulary selections in the future. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Cost-effectiveness of ART strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to cost and formulary considerations, comorbid infections, most notably tuberculosis (TB), malaria, and hepatitis B virus (HBV), are highly prevalent in many developing countries, and pose significant challenges to safe and effective antiretroviral therapy due to drug interactions. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Toxicities associated with treatment of coinfections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since ART is initiated in the setting of more advanced immunosuppression in resource-limited settings than in resource-rich countries, an additional factor that can make drug selection problematic is organ-specific dysfunction associated with advanced HIV disease. Such HIV-related complications include neuropathy, blood dyscrasias, and renal disease, among others.",
"   </p>",
"   <p>",
"    Specific genetic factors may also affect certain drug-associated toxicities. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Central nervous system effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many countries have limited capability or resources to perform laboratory monitoring; thus, early laboratory abnormalities cannot serve as warning signs of pending drug toxicity to guide clinical management. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Monitoring on ART'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITIES ASSOCIATED WITH ART IN RESOURCE-LIMITED SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several toxic syndromes are commonly associated with the use of antiretrovirals in resource-limited settings. Details on the toxicities of individual antiretroviral agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hyperlactatemia and lactic acidosis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hyperlactatemia and the lactic acidosis syndrome are related to chronic administration of nucleoside reverse transcriptase inhibitors (NRTIs), which can lead to mitochondrial toxicity. Clinical manifestations include fatigue, nausea, vomiting, abdominal bloating, weight loss, and hepatomegaly. Hyperlactatemia may be associated with symptoms and elevated lactate levels, while lactic acidosis also leads to severe metabolic derangement with changes in systemic pH. The clinical manifestations and treatment of the patient with lactic acidosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=see_link\">",
"     \"Treatment and prevention of mitochondrial toxicity in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is potential risk of mitochondrial toxicity with all members of the NRTI class, the agents most closely associated with the lactic acidosis syndrome include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    . Combined use of stavudine and didanosine may confer even greater risk than either agent alone. Cases of mitochondrial toxicity are rare with other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and the nucleotide",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ; however, these agents are often not available in resource-limited settings due to cost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted in the developed world, risk factors include female gender, obesity, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study was conducted among 650 treatment-naive HIV-infected adults initiating NRTI-containing ART in Botswana to closely evaluate patients for ART-associated toxicities [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/3\">",
"       3",
"      </a>",
"      ]. During nearly two years of follow-up, 2 percent developed moderate to severe symptomatic hyperlactatemia, defined as serum lactate &gt;4.4",
"      <span class=\"nowrap\">",
"       mmol/L;",
"      </span>",
"      lactic acidosis (symptomatic hyperlactatemia plus pH &lt;7.35 or serum bicarbonate &lt;20",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      developed in 1 percent of the study subjects.",
"     </li>",
"     <li>",
"      A similar incidence of lactic acidosis (approximately 1.3 percent) was found in a retrospective analysis of 1735 adults (63 percent female) initiating ART in Soweto, South Africa [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observed incidence of lactic acidosis in resource-limited settings appears to be higher than the 0.1 to 0.4 percent described in resource-rich studies, and may reflect the more frequent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    . Mortality rates have varied from 7 to 30 percent; in one study, patients with a lower body weight (&lt;45 kg) and higher levels of lactate had increased rates of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In resource-rich settings, serum lactate and pH determination are performed in patients with suspected lactic acidosis syndrome. In areas of limited laboratory capacity, the anion gap may be readily calculated from serum sodium, chloride and bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/4\">",
"     4",
"    </a>",
"    ]. In areas where laboratory monitoring is not available, clinical suspicion of lactic acidosis (eg, symptoms of nausea, vomiting, abdominal discomfort, weight loss, fatigue) should prompt immediate discontinuation of antiretroviral therapy. Identification of an elevated anion gap would be supportive evidence of lactic acidosis syndrome.",
"   </p>",
"   <p>",
"    One study suggested that among 56 patients with mitochondrial toxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    use, switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    -containing ART was safe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/5\">",
"     5",
"    </a>",
"    ]. These data are helpful in patient management since antiretroviral medication selection is mainly limited to older NRTIs in many areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=see_link\">",
"     \"Treatment and prevention of mitochondrial toxicity in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dideoxynucleoside analogues (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ) are the antiretroviral agents most closely associated with pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/7\">",
"     7",
"    </a>",
"    ]. Antiretroviral-induced pancreatitis may be aggravated by, and should be differentiated from, other causes of pancreatitis, such as alcohol use, hyperlipidemia, and cholelithiasis. Clinical symptoms of pancreatitis include abdominal pain, nausea and vomiting; severe pancreatitis can lead to death, particularly in the setting of lactic acidosis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall rate of confirmed pancreatitis is relatively low in studies conducted in resource-limited settings, although limited availability of diagnostic tests may affect the ability to diagnose this complication. In a home-based care program in rural Uganda, 1029 patients with advanced AIDS were followed for clinical signs of antiretroviral toxicity without laboratory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/8\">",
"     8",
"    </a>",
"    ]. Although nearly all patients initiated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    -containing ART, only 0.3 percent received a clinical diagnosis of pancreatitis during a total of 11,268 patient-months of observation. In contrast, a retrospective study conducted in a resource-rich setting found that the incidence rate for clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemical pancreatitis in patients receiving stavudine-containing regimens ranged from 0.77 to 1.84 per 100 person-years, considerably higher than in the Uganda study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of low body weight and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    may increase the risk of pancreatitis. In a retrospective review of 575 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    plus didanosine (a combination that is no longer recommended), didanosine alone, or tenofovir alone, all six cases of pancreatitis occurred in patients who were female, weighed less than 60 kg and received didanosine, either alone (n = 1) or with tenofovir (n = 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    are the agents most frequently associated with peripheral neuropathy followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Other causes of peripheral neuropathy include advanced HIV infection itself, aging, diabetes, and nutritional deficiencies. Concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    or other neurotoxic medications may further increase the risk of peripheral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike the relatively low percentage of patients who develop lactic acidosis or pancreatitis while receiving these agents, peripheral neuropathy occurs in a high percentage of patients, both in resource-rich and resource-poor countries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Kenyan cohort of 1286 patients followed for nearly two years on ART (generally",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      ), 54 percent switched ART regimens; 21 percent of these patients switched because of symptoms of peripheral neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small study of 102 treatment-naive HIV-infected Ugandan patients and 25 HIV-seronegative controls, 54 percent of the treated patients reported foot numbness after six months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      -containing ART, including 38 percent of those with no symptoms at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 199 HIV-infected Kenyans, women were almost 10 times more likely to develop peripheral neuropathy than men during one year of follow-up, after controlling for other factors, such as CD4 cell count, body mass index, ART regimen, and tuberculosis treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite concerns about",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    -induced neuropathy, the mortality benefits of ART outweigh potential neurologic morbidity when no medication alternatives exist. As noted above, in an effort to reduce adverse effects, the WHO has reduced the recommended starting dose of stavudine in adults to 30 mg twice a day regardless of body weight (",
"    <a class=\"external\" href=\"file://www.who.int/hiv/art/ARTadultsaddendum.pdf\">",
"     file://www.who.int/hiv/art/ARTadultsaddendum.pdf",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients who develop this complication, replacement of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    with less toxic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , is suggested when feasible, since switch strategies to alternative agents have been associated with improvements in mitochondrial DNA content and mitochondrial morphology in resource-rich settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Central nervous system effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    may commonly cause acute subjective neurologic symptoms, typically of limited duration, which can impact adherence.",
"   </p>",
"   <p>",
"    The overall frequency of this complication appears to differ by racial group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/16\">",
"     16",
"    </a>",
"    ] and may be related to genetic influences on drug metabolism. The cytochrome (CYP)2B6 516G&gt;T polymorphism (referred to as the",
"    <span class=\"nowrap\">",
"     \"T/T",
"    </span>",
"    genotype\") impairs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    metabolism and occurs more commonly in Africans than in Caucasians. For example, in one study, the",
"    <span class=\"nowrap\">",
"     T/T",
"    </span>",
"    genotype was reported in 3 percent of European-Americans compared with 20 percent of African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/16\">",
"     16",
"    </a>",
"    ]. In another study of 142 HIV-infected patients from South Africa, the prevalence of this genotype was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher prevalence of the",
"    <span class=\"nowrap\">",
"     T/T",
"    </span>",
"    genotype among Africans may explain, in part, reports of increased CNS toxicities such as depression, anxiety, and severe sleep disturbance in Africans, since increased symptoms have been directly related to higher serum drug concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/17\">",
"     17",
"    </a>",
"    ]. If CNS symptoms continue after the first month of treatment, consideration should be given to an alternative therapy, such as a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Central nervous system effects may also be exacerbated if the standard dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (600 mg) is increased to 800 mg daily, as is sometimes done to counter pharmacologic interactions between efavirenz and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    in TB-coinfected patients. However, this dosing strategy has been linked to increased toxicity in patient subsets with the",
"    <span class=\"nowrap\">",
"     T/T",
"    </span>",
"    genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/18\">",
"     18",
"    </a>",
"    ]. If a patient develops significant CNS side effects on efavirenz at the 800 mg dose, consideration should be given to dose reduction, particularly if viral suppression has already been attained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    frequently causes anemia, monitoring of hemoglobin is advisable. Anemia generally occurs during the first six months of zidovudine therapy and may be completely asymptomatic (with only macrocytosis as a marker of zidovudine use) or symptomatic with fatigue or dyspnea. In severe cases, zidovudine-induced anemia can present with life-threatening aplastic crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 3312 treatment-naive patients in Uganda and Zimbabwe, 219 (6.6 percent) on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    -containing regimens exhibited severe anemia (hemoglobin &lt;6.5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    by week 48 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/20\">",
"     20",
"    </a>",
"    ]. This rate is higher than that seen in industrialized nations, and may reflect lower baseline hemoglobin levels secondary to other concomitant infections (such as hookworm or tuberculosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/20\">",
"     20",
"    </a>",
"    ]. Women and those with lower baseline hemoglobin, CD4 cell counts, and body mass index at baseline were at significantly higher risk of developing severe anemia. Reassuringly, the use of cotrimoxazole was not a risk factor for this adverse event.",
"   </p>",
"   <p>",
"    Where laboratory capabilities allow, assessment for other causes of anemia may also be warranted, such as iron deficiency, medication-induced hemolysis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ), or gastrointestinal bleeding. Parvovirus B19 infection, another potential cause of anemia in HIV-infected patients, has been rarely implicated in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/21\">",
"     21",
"    </a>",
"    ], but this may be related to diagnostic limitations. A study in Brazil found parvovirus B19 IgG seropositivity in 62.8 percent of 261 consecutive HIV-infected patients, and suggested that seronegative patients may be at risk of infection during epidemic periods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/22\">",
"     22",
"    </a>",
"    ]. If bone marrow infiltration (eg, by lymphoma or Mycobacterium avium complex), or suppression is suspected (eg, medications), a bone marrow biopsy may be indicated, where feasible.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    use may be even more problematic in areas with high prevalence of certain parasitic coinfections that can exacerbate anemia, such as malaria or hookworm. Tuberculosis may overshadow parasites as a major contributor to anemia in populations with a high prevalence of",
"    <span class=\"nowrap\">",
"     HIV/TB",
"    </span>",
"    coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/23\">",
"     23",
"    </a>",
"    ]. In this situation, treatment of tuberculosis may lead to overall improvement of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since a patient with baseline anemia is at higher risk for increasing severity of anemia after initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , baseline testing with a spun hematocrit would be helpful if laboratory testing is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the introduction of effective antiretroviral therapy, descriptions of patients with body shape abnormalities, such as central fat accumulation and peripheral fat loss emerged [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/3\">",
"     3",
"    </a>",
"    ]. The term \"HIV-associated lipodystrophy syndrome\" was coined, but it soon became clear that some patients have pure lipoatrophy, others have fat accumulation, and a subset of patients have a mixed picture of both morphologic features. Lipodystrophy can also be associated with disorders in glucose and lipid metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In settings where discrimination is still entrenched, stigmatizing physical features (such as malar atrophy) may be particularly detrimental to adherence and patients' well being. Risk factors for lipoatrophy include use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , and to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The frequency of lipodystrophy in resource-limited settings is substantial, which likely reflects the widespread use of medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , which are prone to cause metabolic and body shape changes, such as lipoatrophy. Two studies from Africa demonstrated prevalence rates ranging from 30 to 70 percent; stavudine was a significant predictor of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from developed countries suggest that use of protease inhibitors (PIs) may be a significant factor in lipodeposition; however, there is limited information on the role of PIs in lipodystrophy syndromes in resource-limited settings at this time because this class of antiretrovirals is infrequently prescribed.",
"   </p>",
"   <p>",
"    Treatment for lipoatrophy is essentially limited to discontinuation of the offending agent; however, clinical improvement is exceedingly slow and full recovery may not necessarily occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;All antiretroviral agents can cause hepatotoxicity, although different drugs vary in their propensity to cause liver damage.",
"   </p>",
"   <p>",
"    Of the NRTIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    are the most likely to cause hepatotoxicity, probably because of the mitochondrial effects of these agents. Full-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is the most hepatotoxic of the PIs, but this drug is rarely used at such doses anymore; when used as a low-dose pharmacologic booster of other agents, ritonavir is less commonly associated with liver injury. Of the non-nucleoside reverse transcriptase inhibitors (NNRTIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is more likely to cause hepatotoxicity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in patients with detectable viremia. However, in resource-rich settings, nevirapine appears to be relatively safe in patients with viral suppression who are switched to this agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    hepatotoxicity is concentrated in certain risk groups. In a prospective cohort study of 146 pregnant females in Mozambique, severe hepatotoxicity was more common in those with CD4 cell count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    compared with patients whose CD4 cell count was &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    (6 percent versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/27\">",
"     27",
"    </a>",
"    ]. Having a CD4 count &gt;400",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    has been identified as a risk factor for nevirapine hepatotoxicity in men; at this time, this finding is less relevant in resource-limited settings because such patients rarely meet current WHO or national guidelines for ART initiation. Nevirapine can also be associated with a hypersensitivity reaction, as discussed below.",
"   </p>",
"   <p>",
"    Coinfection with viral hepatitis also increases the likelihood of ART-induced hepatotoxicity. For example, in a Nigerian study of 1564 patients, the risk for serious hepatotoxicity 24 weeks after initiation of ART was 3.1 percent in patients coinfected with HBV compared with only 0.5 percent in patients with HIV alone; hepatotoxicity was not associated with either baseline HBV DNA concentration or HBeAg status [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/28\">",
"     28",
"    </a>",
"    ]. Coinfection with hepatitis C is an important risk factor as well, but this diagnosis tends to be more common in resource-rich areas.",
"   </p>",
"   <p>",
"    Other risk factors for ART-related liver injury include concomitant use of other hepatotoxic drugs (such as antituberculous agents or herbal remedies) and the presence of abnormalities of aminotransferases at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though virtually any drug can cause a hypersensitivity syndrome,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    are associated with uncommon but well-documented life-threatening reactions. Prior to starting patients on these medications, the clinician should discuss potential symptoms that would alert the patient to the possibility of this reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common concomitant medications such as antituberculous medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), beta-lactam antibiotics, and herbal remedies may provoke hypersensitivity reactions (HSR) as well. Thus, it is important to consider all medications as potential causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nevirapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;This agent accounts for over three-fourths of NNRTI prescriptions in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/29\">",
"     29",
"    </a>",
"    ]. Hypersensitivity reactions (HSR) may present with rash, fever, hepatitis, or eosinophilia, usually during the first 16 weeks of therapy. In a Ugandan cohort of 1029 patients studied during a 19-month period, the incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    HSR was 1.7 percent, including one death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/8\">",
"     8",
"    </a>",
"    ]. Rechallenge with nevirapine is contraindicated after an HSR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    HSR is more common in women with CD4 cell count &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and men with CD4 cell count &lt;400",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    The risk of nevirapine HSR is related to the pretreatment CD4 cell count and the presence of HIV viremia. Thus, if the patient's CD4 count rises to &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    on treatment, nevirapine does not need to be discontinued. Also, the risk of hypersensitivity reaction is mitigated when viral suppression has already been achieved. Thus, switching a patient to nevirapine due to an adverse event related to another drug is much less likely to lead to HSR if viral suppression has already been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/30\">",
"     30",
"    </a>",
"    ]. Lead-in dosing (eg, 200 mg daily for 14 days followed by twice-daily dosing) is recommended to decrease the risk of adverse events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Abacavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the HLA-B*5701 allele greatly increases the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    HSR, and its absence markedly reduces the risk of an immunologic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for HLA-B*5701 has become the standard of care in many developed countries, but is rarely available in resource-limited settings. Fortunately, this haplotype is rare in Africans; thus, it appears",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    can be used relatively safely in this population with close monitoring. Of 599 Ugandan patients, only 2 percent of those randomly assigned to abacavir experienced an HSR compared with 4.7 percent who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern that the prevalence of nephrotoxicity may increase as the nucleotide reverse transcriptase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , becomes more widely available in Sub-Saharan Africa. Tenofovir use has been associated with renal insufficiency, particularly in patients with preexisting diabetes or hypertension.",
"   </p>",
"   <p>",
"    However, in an observational study of 3316 treatment-naive patients in Zimbabwe and Uganda, despite high prevalence of baseline mild to moderate renal insufficiency and common use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (74 percent), severe renal dysfunction after 96 weeks was rare, and tenofovir-free regimens offered only marginal benefit in improving baseline glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/33\">",
"     33",
"    </a>",
"    ]. This finding is particularly reassuring since prior to treatment, 45 and 7 percent of the patient population had mild or moderate renal insufficiency, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    also has dual activity against hepatitis B and is often prescribed to patients with HBV coinfection in several countries, including South Africa and Nigeria. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'HIV/hepatitis B coinfection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, diffuse muscle fatigue or weakness, generally of insidious onset, can result from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients must be monitored for zidovudine-related myopathy through careful history and physical examination. If laboratory monitoring is available, a creatine kinase should also be checked in suspected cases; when elevated, a muscle biopsy may be considered. Zidovudine should be discontinued if this diagnosis is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link\">",
"     \"Muscle disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin eruptions are a common complication of NNRTIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . A case-control study was performed among Thai patients who developed rash after starting nevirapine-containing ART compared with patients who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/35\">",
"     35",
"    </a>",
"    ]. Risk factors for the development of rash included a prior history of drug allergy and low body weight; risk was also elevated with higher CD4 cell counts (odds ratio, 1.2 per each 50",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    increment).",
"   </p>",
"   <p>",
"    If a rash occurs, it is generally safe to continue therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    with close monitoring of the patient. However, it is crucial to distinguish self-limited mild drug rash from life-threatening, systemic reactions, such as Stevens-Johnson Syndrome (SJS) or hypersensitivity reaction (HSR), which have both been described in association with nevirapine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Rash that is associated with mucosal involvement (eyes, mouth) suggests SJS, while constitutional symptoms, fever, and eosinophilia suggest HSR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24538?source=see_link\">",
"     \"Fever and rash in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consideration should also be given to other potential etiologies of rash, such as medications (notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ), concomitant infections (eg, secondary syphilis) or worsening of eczematous rashes or eosinophilic folliculitis during ART-associated immune reconstitution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gastrointestinal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease inhibitors often cause diarrhea, which may or may not be self-limited. If the diarrhea persists, opportunistic infections (eg, Mycobacterium avium intracellulare) should be excluded, especially in patients with advanced immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dyslipidemia and metabolic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal fasting lipid profiles and impaired glucose tolerance are common among patients on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/25\">",
"     25",
"    </a>",
"    ]. In the NRTI class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    are more likely to be associated with dyslipidemia than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . Amongst the NNRTIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is more likely to cause dyslipidemia than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , which is associated with favorable increases in HDL-c.",
"   </p>",
"   <p>",
"    Lipid profiles were monitored at 12 and 24 months after the initiation of ART in 374 patients in Uganda, the vast majority of whom were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/38\">",
"     38",
"    </a>",
"    ]. After 24 months, increases in HDL-cholesterol levels were substantial and proportionally greater than increases in total cholesterol or LDL-c levels, which was likely related to nevirapine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is prevalent in many resource-limited settings and traditional cardiac risk factors may be on the rise. According to statistics from the WHO, cardiovascular deaths (including coronary artery disease and cerebrovascular disease) comprise 15 percent of all deaths in low-income countries, substantially greater than the 5.7 percent of deaths from",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/39\">",
"     39",
"    </a>",
"    ]. A survey performed among persons living in rural and urban communities in South Africa assessed the influence of urbanization on nutritional status and overall health [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/40\">",
"     40",
"    </a>",
"    ]. This study documented that those living in urban settings had elevated levels of LDL-c and total cholesterol, higher rates of obesity, and significantly higher proportions of persons with elevated systolic blood pressure than those living in rural areas.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    have been associated with an increased likelihood of myocardial infarction in some studies in resource-rich settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/41\">",
"     41",
"    </a>",
"    ], though these associations remain controversial and the underlying mechanisms have not been conclusively elucidated. Further research is needed to define the impact of antiretroviral medications on cardiovascular disease in low-income nations undergoing lifestyle changes as a result of industrialization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Special considerations during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Females of childbearing potential are disproportionately affected by HIV infection in resource-limited settings. Pregnancy is common because many infected men and women remain sexually active in the absence of effective contraception and there are strong social pressures to procreate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The teratogenic potential of certain antiretroviral medications and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    in pregnancy for maternal health or prevention of mother-to-child transmission are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .) Due to neural tube defects observed in monkey studies and a few clinical cases observed in humans,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is classified as a Pregnancy Category D drug and is best avoided in women who are planning to or may become pregnant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     IMPACT OF NONTRADITIONAL/HERBAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of herbal remedies is common among HIV-infected patients in many parts of Africa. For example, in the Kabrole District of Western Uganda, 63.5 percent of patients reported herbal remedy use after HIV diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/44\">",
"     44",
"    </a>",
"    ]. In KwaZulu-Natal, South Africa, 51 percent of 618 patients reported using traditional complementary and alternative medicines in the preceding six months, but only 10 percent had informed their healthcare provider [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some traditional herbs may affect the metabolism of antiretrovirals, placing patients at risk for treatment failures or toxicities. Two herbs commonly used by traditional healers to treat HIV in South Africa, hypoxis and Sutherlandia, affect the CYP3A4 enzyme pathways in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/46\">",
"     46",
"    </a>",
"    ] and could lead to unpredictable drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MONITORING ON ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO provides clinical and laboratory monitoring guidelines for patients on ART, which may facilitate earlier detection of antiretroviral toxicities and decreased morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given a wide range of monitoring capabilities in different facilities among many countries, providers may need to adapt guidelines to their locale. Some studies have shown that provision of ART with no routine laboratory monitoring can be successful. In the home-based care program in rural Uganda mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/8\">",
"     8",
"    </a>",
"    ], nearly all patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    +",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    +",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    without laboratory monitoring. The most common clinical toxicities (peripheral neuropathy and rash) were typically managed with single-drug substitutions, and no patients discontinued ART because of toxicity. In areas where laboratory capabilities are comparable to resource-rich settings, adaptation of monitoring guidelines for resource-rich settings is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link&amp;anchor=H19#H19\">",
"     \"The global human immunodeficiency virus pandemic\", section on 'Laboratory monitoring'",
"    </a>",
"    .) For more information, see Table 3 of the DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents, which can be accessed at",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf\">",
"     file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TOXICITIES ASSOCIATED WITH TREATMENT OF COINFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     HIV/tuberculosis coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2007, there were 1.37 million cases of",
"    <span class=\"nowrap\">",
"     HIV/tuberculosis",
"    </span>",
"    coinfection worldwide, and 80 percent of these were in sub-Saharan Africa. Tuberculosis is the leading cause of death among people living with HIV in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/48\">",
"     48",
"    </a>",
"    ], and successful management of",
"    <span class=\"nowrap\">",
"     HIV/TB",
"    </span>",
"    coinfection is critical to achieve reductions in mortality.",
"   </p>",
"   <p>",
"    Drug interactions between antiretrovirals and antituberculous medications and overlapping toxicities are among the most challenging aspects of HIV care in resource-limited settings. For example, a patient with tuberculosis may have significant anemia at baseline, which may compound the bone marrow suppressive effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    . Detailed information about the use of specific anti-tuberculosis medications and antiretroviral medications is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hepatotoxicity with antituberculous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of hepatotoxicity during coadministration of ART and antituberculous therapy range from 6 to 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/49\">",
"     49",
"    </a>",
"    ]. Pre-existing liver disease likely increases the risk of hepatotoxicity, which is particularly important in areas of high prevalence of viral hepatitis. A variety of management approaches have been used in this situation, but the cardinal principle involves discontinuation of the offending agent(s).",
"   </p>",
"   <p>",
"    An observational cohort study of Indian patients with HIV infection and CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    initiating ART with EFV plus two NRTIs (mostly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    +",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) compared rates of adverse events in patients simultaneously starting antituberculous therapy (n = 126) to patients without TB (n = 129) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/50\">",
"     50",
"    </a>",
"    ]. During a nine-month period, hepatitis was significantly more prevalent in patients receiving antituberculous therapy (13.5 percent versus 0 percent), though the group with TB had a slightly lower median baseline CD4 count (84 versus 118",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"    These observed differences may be related to inherent drug-induced liver injury or to immune recovery and the immune reconstitution inflammatory syndrome (IRIS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .) Interestingly, all patients had resolution of hepatitis within one month of discontinuing the most hepatotoxic agents in their regimens (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    ) and continuing with a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    . Stepwise reintroduction of the potentially hepatotoxic agents after normalization of aminotransferases was pursued, but the study did not present long-term outcomes for these patients.",
"   </p>",
"   <p>",
"    Other common toxicities associated with coadministration of antiretroviral and antituberculous medications include rash, gastrointestinal distress,",
"    <span class=\"nowrap\">",
"     leukopenia/neutropenia,",
"    </span>",
"    anemia, and CNS side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     HIV/hepatitis B coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B coinfection is common in many developing countries and increases the risk of hepatotoxicity from ART by three to fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential causes of hepatic injury, however, should be considered when evaluating a patient for possible ART-induced hepatotoxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      is the only HBV-active agent in most regimens used in resource-limited settings and screening for this infection is rarely performed. Thus, most coinfected patients receive lamivudine monotherapy for HBV, which places them at risk of lamivudine resistance with hepatitis flares [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/52\">",
"       52",
"      </a>",
"      ]; the incidence of this complication in resource-limited settings is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"       \"Treatment of hepatitis B in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interruption of antiretroviral agents with activity against hepatitis B virus (which may occur in poorly adherent patients) may precipitate hepatitis B exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatitis B flares may occur in the setting of immune recovery after initiation of ART, despite the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these scenarios may be difficult to discriminate from ART-induced liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     HIV/hepatitis C coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C infection can increase the risk of ART-induced liver injury. However, HCV diagnostics and treatment are not widely available in resource-limited settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data exist on additive toxicities between drugs used to treat malaria and antiretrovirals. Of note, a study designed to evaluate pharmacokinetic interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and amodiaquine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    in five healthy patients was prematurely terminated after the first two participants developed significant hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=see_link\">",
"     \"HIV and malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     EARLY MORTALITY AFTER INITIATION OF ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated increased rates of early mortality after initiation of ART in resource-limited settings, which may be related to tuberculosis, IRIS, or more severe baseline immune suppression compared with patients in resource-rich settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS OF ART STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of less toxic agents is the most commonly cited reason for the continued use of relatively toxic regimens in many resource-limited settings. For example, although the World Health Organization considers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    to be preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    due to its relatively lower toxicity, stavudine-based regimens remain in widespread use as a fixed-dose combination of stavudine +",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    +",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , which costs half as much as zidovudine + lamivudine + nevirapine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One cost-effectiveness analysis demonstrated that use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    would be cost-effective if the price of tenofovir was approximately 25 percent lower than it is currently [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/56\">",
"     56",
"    </a>",
"    ]. Another analysis of first-line ART regimens in India demonstrated that tenofovir was cost-effective because its better efficacy and toxicity profile led to lower mortality rates and fewer treatment switches [",
"    <a class=\"abstract\" href=\"UTD.htm?10/34/10794/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV treatment regimens in resource-limited settings frequently contain older antiretrovirals that are more likely to have adverse effects than newer, more expensive agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Special treatment considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to become familiar with toxicities that are commonly seen with the chronic administration of antiretroviral medications in order to recognize these adverse events in a timely manner. Early recognition and discontinuation of the offending agent can decrease morbidity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicities associated with ART in resource-limited settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Herbal remedies are commonly used and may have unpredictable drug interactions and overlapping toxicities with antiretroviral medications. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Impact of nontraditional/herbal therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring for early signs of toxicities can minimize the likelihood of adverse events; monitoring guidelines may need to be adjusted to reflect local capabilities and resources. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Monitoring on ART'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coinfection with malaria, tuberculosis, and viral hepatitis, which are common in resource-limited settings, can complicate the treatment of both HIV and the concomitant infection through added drug toxicity and drug interactions. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Toxicities associated with treatment of coinfections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 Revision. Geneva 2006.",
"    </li>",
"    <li>",
"     WHO \"Rapid Advice\" document. file://www.who.int/hiv/pub/arv/rapid_advice_art.pdf (Accessed on May 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/3\">",
"      Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/4\">",
"      Geddes R, Knight S, Moosa MY, et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/5\">",
"      Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/6\">",
"      Manosuthi W, Prasithsirikul W, Chumpathat N, et al. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis 2008; 12:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/7\">",
"      Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005; 39:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/8\">",
"      Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/9\">",
"      Mart&iacute;nez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/10\">",
"      Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 2007; 45:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/11\">",
"      Sacktor N, Nakasujja N, Skolasky RL, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009; 72:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/12\">",
"      Ait-Mohand H, Bonmarchand M, Guiguet M, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med 2008; 9:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/13\">",
"      Kumarasamy N, Venkatesh KK, Cecelia AJ, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 2008; 22:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/14\">",
"      Mehta SA, Ahmed A, Laverty M, et al. Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis 2011; 53:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/15\">",
"      Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/16\">",
"      Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/17\">",
"      Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/18\">",
"      Brennan-Benson P, Lyus R, Harrison T, et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/19\">",
"      Hassan A, Babadoko AA, Mamman AI, Ahmed SA. Zidovudine induced pure red cell aplasia: a case report. Niger J Med 2009; 18:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/20\">",
"      Ssali F, St&ouml;hr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006; 11:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/21\">",
"      Sanphasitvong W, Poovorawan K, Boonsuk P, et al. Parvovirus b19 infection in HIV patient with pure red cell aplasia. Southeast Asian J Trop Med Public Health 2005; 36:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/22\">",
"      Azevedo KM, Set&uacute;bal S, Camacho LA, et al. Seroepidemiological study of human parvovirus B19 among human immunodeficiency virus-infected patients in a medium-sized city in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 2009; 104:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/23\">",
"      Lewis DK, Whitty CJ, Walsh AL, et al. Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg 2005; 99:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/24\">",
"      Mercier S, Gueye NF, Cournil A, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr 2009; 51:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/25\">",
"      Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/26\">",
"      Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/27\">",
"      Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/28\">",
"      Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/29\">",
"      Renaud-Th&eacute;ry F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 2007; 21 Suppl 4:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/30\">",
"      Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis 2008; 46:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/31\">",
"      Bonta PI, Vermeulen JN, Speelman P, Prins JM. Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. AIDS 2008; 22:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/32\">",
"      Dart Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008; 13:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/33\">",
"      Reid A, St&ouml;hr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/34\">",
"      Till M, Kochvar G, Murphy R, Phair J. Myopathy associated with zidovudine use in HIV-1 infection. Int Conf AIDS 1992; 9:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/35\">",
"      Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, et al. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008; 6:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/36\">",
"      Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 2002; 35:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/37\">",
"      Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/38\">",
"      Buchacz K, Weidle PJ, Moore D, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008; 47:304.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Fact sheet number 310. Top 10 Causes of Death. November 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/40\">",
"      Vorster HH, Venter CS, Wissing MP, Margetts BM. The nutrition and health transition in the North West Province of South Africa: a review of the THUSA (Transition and Health during Urbanisation of South Africans) study. Public Health Nutr 2005; 8:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/41\">",
"      Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/42\">",
"      Nebi&eacute; Y, Meda N, Leroy V, et al. Sexual and reproductive life of women informed of their HIV seropositivity: a prospective cohort study in Burkina Faso. J Acquir Immune Defic Syndr 2001; 28:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/43\">",
"      Forsyth AD, Coates TJ, Grinstead OA, et al. HIV infection and pregnancy status among adults attending voluntary counseling and testing in 2 developing countries. Am J Public Health 2002; 92:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/44\">",
"      Langlois-Klassen D, Kipp W, Jhangri GS, Rubaale T. Use of traditional herbal medicine by AIDS patients in Kabarole District, western Uganda. Am J Trop Med Hyg 2007; 77:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/45\">",
"      Peltzer K, Preez NF, Ramlagan S, Fomundam H. Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa. BMC Public Health 2008; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/46\">",
"      Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Consultation on Technical and Operational Recommendations for Scale-Up of Laboratory Services and Monitoring HIV Antiretroviral Therapy in Resource-Limited Settings. 2004, Geneva, Switzerland.",
"    </li>",
"    <li>",
"     Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/49\">",
"      McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/50\">",
"      Patel A, Patel K, Patel J, et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/51\">",
"      Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/52\">",
"      Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/53\">",
"      McGovern B. What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both? Clin Infect Dis 2004; 39:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/54\">",
"      German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007; 44:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/55\">",
"      Laurent C, Bourgeois A, Mpoudi-Ngol&eacute; E, et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses 2008; 24:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/56\">",
"      Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008; 48:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/34/10794/abstract/57\">",
"      Bender MA, Kumarasamy N, Mayer KH, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 2010; 50:416.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3758 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10794=[""].join("\n");
var outline_f10_34_10794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPECIAL TREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cost considerations in formulary selections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITIES ASSOCIATED WITH ART IN RESOURCE-LIMITED SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hyperlactatemia and lactic acidosis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Central nervous system effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nevirapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Abacavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gastrointestinal complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dyslipidemia and metabolic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Special considerations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      IMPACT OF NONTRADITIONAL/HERBAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MONITORING ON ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TOXICITIES ASSOCIATED WITH TREATMENT OF COINFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      HIV/tuberculosis coinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hepatotoxicity with antituberculous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HIV/hepatitis B coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      HIV/hepatitis C coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      EARLY MORTALITY AFTER INITIATION OF ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      COST-EFFECTIVENESS OF ART STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=related_link\">",
"      Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24538?source=related_link\">",
"      Fever and rash in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=related_link\">",
"      HIV and malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=related_link\">",
"      Monitoring the HIV-infected patient on antituberculous medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33494?source=related_link\">",
"      Treatment and prevention of mitochondrial toxicity in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_34_10795="Evaluation dermatoses pregnancy";
var content_f10_34_10795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of dermatoses in pregnant women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Obtain a detailed medical, family, obstetrical, and current illness history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Perform a physical examination focusing on the distribution and morphology of the lesions:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Involvement of striae is common in PUPPP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nodular lesions on the limbs suggest prurigo of pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Urticarial lesions are most common with PUPPP or pemphigoid gestationis, which also can display vesicular lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Laboratory evaluation depends upon the physical findings. Laboratory studies (eg, bile acids, liver function, prothrombin time) are indicated when cholestasis is suspected because of the risks of maternal and fetal morbidity.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skin biopsy is indicated if the diagnosis is in question or to confirm pemphigoid gestationis.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10795=[""].join("\n");
var outline_f10_34_10795=null;
var title_f10_34_10796="Classification thymic neuroendocrine tumors";
var content_f10_34_10796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of thymic neuroendocrine carcinomas (NEC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Well differentiated NEC",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Poorly differentiated NEC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Typical carcinoid",
"       </td>",
"       <td class=\"subtitle2\">",
"        Atypical carcinoid",
"       </td>",
"       <td class=\"subtitle2\">",
"        LCNEC",
"       </td>",
"       <td class=\"subtitle2\">",
"        SCC, neuroendocrine type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No necrosis; &lt;2 mitoses per 2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPF)",
"       </td>",
"       <td>",
"        Necrosis present and/or 2-10 mitoses per 2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPF)",
"       </td>",
"       <td>",
"        Non-small cell NEC with &gt;10 mitoses per 2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPF)",
"       </td>",
"       <td>",
"        Small cell cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Morphological variants:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Spindle cell type",
"         </li>",
"         <li>",
"          Pigmented type",
"         </li>",
"         <li>",
"          With amyloid (extrathyroidal medullary carcinoma)",
"         </li>",
"         <li>",
"          Oncocytic/oxyphilic type",
"         </li>",
"         <li>",
"          Mucinous",
"         </li>",
"         <li>",
"          Angiomatoid type",
"         </li>",
"         <li>",
"          Combinations of the above variants",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Variants:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          SCNEC combined with non-NECs",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <p>",
"         Thymic NECs with shared features of (atypical) carcinoid and LCNEC/SCC",
"        </p>",
"        Carcinoid with sarcomatous change (\"metaplastic NEC\")",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LCNEC: large cell neuroendocrine carcinoma; SCC: small cell carcinoma; HPF: high power field.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds), IARC Press, Lyon, 2004. Copyright &copy; 2004 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10796=[""].join("\n");
var outline_f10_34_10796=null;
var title_f10_34_10797="BMD after liver transplantation";
var content_f10_34_10797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone loss after liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rate of change in lumbar spine bone mineral density (LS-BMD) after orthotopic liver transplantation in 105 women with primary biliary cirrhosis. Most women had a substantial loss of LS-BMD (mean rate 18.1 percent per year) at three months. Measurements at 12, 24, and 36 months showed stable BMD with evidence for recovery of bone loss in some women at 12 months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eastell R, Dickson ER, Hodgson SF, et al. Hepatology 1996; 14:296.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10797=[""].join("\n");
var outline_f10_34_10797=null;
var title_f10_34_10798="Obstructing CBD stone ERCP";
var content_f10_34_10798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obstructing stone in common bile duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following cannulation of the distal common bile duct during an endoscopic retrograde cholangiopancreatography examination (black arrow indicates cannula), contrast material was injected, outlining a large stone producing complete obstruction of the distal duct (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10798=[""].join("\n");
var outline_f10_34_10798=null;
var title_f10_34_10799="TR subcostal with color Doppler echo";
var content_f10_34_10799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/60413/subctrre_conv.mp4?title=TR+subcostal+with+color+Doppler+echo\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal view from a 2-D echocardiogram with color flow Doppler shows retrograde flow into dilated hepatic veins as a result of severe tricuspid regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_34_10799=[""].join("\n");
var outline_f10_34_10799=null;
